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abbreviations
AASI Ambulatory arterial stiffness index
ABPM Ambulatory blood pressure measurement
ACE Angiotensin-converting enzyme
AIx Aortic augmentation index
Ang I Angiotensin I
Ang II  Angiotensin II
AR Adrenergic receptor
AT1 Angiotensin II type 1 receptor
AT2 Angiotensin II type 2 receptor
AUC Area under the curve
BMI Body mass index
cGMP Cyclic guanosine -3’,5’-monophosphate
CAGE Chymostatin-sensitive angiotensin II-generating enzyme
COX Cyclooxygenase
CRP C-reactive protein
CVD Cardiovascular disease
DASH Dietary Approaches and Stop Hypertension
DBP Diastolic blood pressure
dTGR Double transgenic rats
EDHF Endothelium-derived hyperpolarizing factor
ESC European Society of Cardiology
ESH European Society of Hypertension
ET Endothelin
HPLC High Performance Liquid Chromatography
Ile-Pro-Pro (IPP)  Isoleucyl-prolyl-proline
JNC Joint National Committee
LC-MS Liquid chromatography-mass spectrometry
NEP Neutral endopeptidase
NHANES National Health and Nutrition Examination Survey
NO Nitric oxide
NOS Nitric oxide synthase
PGI2 Prostacyclin
PRA Plasma renin activity
PWA Pulse wave analysis
RAS Renin-angiotensin system
SBP Systolic blood pressure
SD Standard deviation
SHR Spontaneously hypertensive rats
t-PA Tissue plasminogen activator
Tr Time to return of the reflected wave
TXA2 Thromboxane A2
Val-Pro-Pro (VPP) Valyl-prolyl-proline
WHO-ISH The World Health Organization and the International Society 
of Hypertension
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abstraCt
The purpose of the present study was to evaluate the effects of Lactobacillus 
helveticus fermented milk (peptide milk) containing the casein-derived tripeptides 
Isoleucyl-prolyl-proline (Ile-Pro-Pro) and Valyl-prolyl-proline (Val-Pro-Pro) on 
blood pressure and vascular function in hypertensive subjects. 
The peptide milk lowered systolic and diastolic blood pressure in long-term 
use in hypertensive subjects when blood pressure was measured by using 24-hour 
ambulatory blood pressure measurement (ABPM). The blood pressure lowering 
effect was seen with the dose of 50 mg of tripeptides, and a tendency for lowering 
blood pressure was also observed when the dose was 5 mg. No adverse effects 
compared to the placebo group were reported or detected in laboratory analysis. 
The effect of the peptide milk on arterial stiffness was shown using two 
different methods, the ambulatory arterial stiffness index (AASI) and pulse wave 
analysis (PWA). According to the AASI, arterial stiffness was significantly reduced 
in the peptide milk group compared to the baseline level, but the difference was 
not significant compared to the placebo group. PWA showed that the peptide 
milk reduced arterial stiffness significantly compared to the placebo group. 
Endothelium-independent relaxation (nitroglycerin) and endothelium-dependent 
relaxation (salbutamol) did not differ between the groups. 
The blood pressure lowering mechanisms of the tripeptides and the kinetics 
of Ile-Pro-Pro were investigated using spontaneously hypertensive rats (SHR) 
and Sprague-Dawley rats. Previous studies have suggested that the blood 
pressure lowering effect of the tripeptides Ile-Pro-Pro and Val-Pro-Pro is based 
on angiotensin-converting enzyme inhibition, but the present findings did not 
agree with these previous studies. It was shown in SHR that calcium, potassium 
and magnesium may also have an important role in attenuating the development 
of hypertension as part of the peptide milk effect. In addition, the present study 
suggests indirectly that improved endothelial nitric oxide release capacity is not the 
mechanism by which peptide milk mediates its favourable circulatory effects.
The kinetics of Ile-Pro-Pro were studied using adult Sprague-Dawley rats. 
The results showed that orally administered Ile-Pro-Pro is absorbed at least partly 
intact from the gastrointestinal tract. Radiolabelled Ile-Pro-Pro was distributed in 
different tissues and considerable radioactivity levels were found in tissues related 
to the renin-angiotensin system (RAS), adrenals, aorta and kidneys. Ile-Pro-Pro 
10
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does not bind to plasma proteins, and therefore it is possible that its blood pressure 
lowering effect is mediated by free Ile-Pro-Pro.
In conclusion, consumption of the peptide milk lowers blood pressure and 
reduces arterial stiffness in hypertensive subjects. Ile-Pro-Pro can be absorbed partly 
intact from the gastrointestinal tract and might accumulate in tissues related to the 
RAS. The precise blood pressure lowering mechanism of peptide milk remains to 
be studied. 
11
I N T R O D U C T I O N
Hypertension is a major risk factor for cardiovascular diseases, including heart 
failure, coronary heart disease, peripheral artery disease and stroke. Hypertension 
is a worldwide health problem and can cause serious complications as well as 
significant costs to society. Expenditure on the prevention or early identification 
and subsequent treatment of hypertension, both with and without medication, are 
thus well worthwhile ways to reduce the overall risk of cardiovascular morbidity 
and mortality (Chobanian et al. 2003; Whitworth 2003; Mancia et al. 2007). 
Endothelial dysfunction is another risk factor for cardiovascular diseases, and 
it has been associated with cardiovascular risk factors such as hypertension and 
dyslipidaemia (Panza et al. 1990; Mensah et al. 2007; for reviews, see Vapaatalo and 
Mervaala 2001; Vanhoutte 2003). Evidence of an association between endothelial 
dysfunction and arterial stiffness has been demonstrated (Wilkinson et al. 2002b). 
Arterial stiffness is an independent predictor of cardiovascular morbidity and 
mortality (Dart et al. 1993; Boutouyrie et al. 2002).
Life-style factors, such as nutrition (for reviews, see Karppanen 1991; Nurminen 
et al. 1998; Myers and Champagne 2007), moderation of alcohol use (Xin et al. 
2001), physical activity (Hagberg et al. 2000), weight reduction in those who 
are overweight (He et al. 2000) and abstinence from smoking (Doll et al. 2004) 
have a considerable impact on the treatment and prevention of hypertension and 
in lowering cardiovascular risks. Several studies have shown that a low intake of 
sodium (Cutler et al. 1997; Graudal et al. 1998; Kotchen and McCarron 1998; 
Sacks et al. 2001) and a sufficient intake of calcium (Allender et al. 1996; Bucher 
et al. 1996; van Mierlo et al. 2006), potassium (Cappuccio and MacGregor 1991; 
Whelton et al. 1997) and magnesium (Mervaala et al. 1992; Ascherio et al. 1998) 
help to prevent the development of hypertension. Epidemiological studies suggest 
1  Introduction
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that milk consumption and dietary intake of dairy proteins are inversely related to 
the risk of hypertension (McCarron et al. 1984; He and Whelton 1999; Ruidavets et 
al. 2006). Some intervention studies have shown milk products and dairy proteins 
to have a blood pressure lowering effect (Appel et al. 1997; Burke et al. 2001). Several 
milk peptides have been shown to have antihypertensive effects in both animal and 
clinical studies (for reviews, see FitzGerald et al. 2004; Korhonen and Pihlanto 
2006). The most widely studied mechanism underlying the antihypertensive 
effects of milk peptides is the inhibition of angiotensin-converting enzyme (ACE) 
(for reviews, see FitzGerald and Meisel 2000; López-Fandiño et al. 2006). The 
milk-derived peptides have also been shown to have beneficial effects on vascular 
endothelium and also on arterial tone, but so far, this has been shown only in vitro 
(Sipola 2002; Sipola et al. 2002b). 
The purpose of the present study was to evaluate the long-term blood pressure 
lowering effects of the Lactobacillus helveticus fermented milk (peptide milk) 
containing the casein-derived tripeptides Isoleucyl-prolyl-proline (Ile-Pro-Pro) 
and Valyl-prolyl-proline (Val-Pro-Pro) using different blood pressure measurement 
techniques and to assess the effects of the peptide milk on arterial stiffness in clinical 
studies. Another purpose was to investigate the antihypertensive mechanisms of 
Ile-Pro-Pro and Val-Pro-Pro and the kinetics of Ile-Pro-Pro in animal models.
13
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2.1 HYPERTENSION
Hypertension is a common health problem in all Western countries. It is a major 
risk factor for cardiovascular diseases including coronary heart disease, peripheral 
artery disease and stroke. Untreated hypertension can therefore cause significant 
health problems as well as significant costs to society.
2.1.1 Blood pressure and the definition of hypertension
Cardiac output and total peripheral resistance are the factors which finally 
determine blood pressure. In hypertension, either the cardiac output, the peripheral 
resistance or both are elevated. Increased fluid volume and increased sympathetic 
neural system stimulation of the heart raise cardiac output. However, in most 
hypertensive subjects, the typical haemodynamic finding is normal cardiac output 
and elevated peripheral resistance (Cowley 1992). The cause of hypertension is 
unknown in about 95% of cases (essential hypertension). Genetic factors have been 
estimated to account for about 30% of the variation in blood pressure, and subjects 
with one or two hypertensive parents have hypertension twice as often as subjects 
without this genetic background (for review, see Beevers et al. 2001b). 
The World Health Organization and the International Society of Hypertension 
(WHO-ISH 2003) have defined the normal blood pressure values as a systolic 
blood pressure of less than 130 mmHg and a diastolic blood pressure of less than 
85 mmHg. Blood pressure values of 140-159 mmHg (systolic) and 90-99 mmHg 
(diastolic) are defined as mild hypertension (Whitworth 2003) (Table 1). The 
European Society of Hypertension (ESH) and the European Society of Cardiology 
(ESC) have the same definition for normal blood pressure as WHO-ISH and 
2  R ev iew of 
the Liter ature
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define a systolic blood pressure of 140-159 mmHg and a diastolic blood pressure 
of 90-99 mmHg as grade 1 hypertension (Mancia et al. 2007). The Joint National 
Committee (JNC 7), on the other hand, defines normal systolic blood pressure as 
less than 120 mmHg and diastolic as less than 80 mmHg. In the JNC 7 guidelines, 
hypertension has been divided into two stages. Stage 1 refers to systolic blood 
pressure values of 140-159 mmHg or diastolic values of 90-99 mmHg, while stage 
2 means systolic blood pressure values of more than 160 mmHg or diastolic values 
of more than 100 mmHg (Chobanian et al. 2003). 
Table 1. Blood pressure classification according to WHO-ISH (Whitworth 2003). 
Blood pressure  
classification
Systolic blood 
pressure, mmHg
Diastolic blood  
pressure, mmHg
Optimal <120 <80
Normal <130 <85
High-normal 130–139 85–89
Mild hypertension, grade 1 140–159 90–99
Moderate hypertension, grade 2 160–179 100–109
Severe hypertension, grade 3 ≥180 ≥110
2.1.2 Prevalence of hypertension
The worldwide prevalence of hypertension was approximately 26% in the adult 
population in 2000 (Kearney et al. 2005). It is estimated that this prevalence is 
rising among the aging population, along with increasing obesity and less physical 
activity. The Framingham Heart Study suggests that normotensive subjects 
aged 55 to 65 have a 90% risk of developing hypertension during their lifetime 
(Vasan et al. 2002). At the end of 2006, about 500 000 people in Finland used 
antihypertensive medication, according to the Social Insurance Institution (The 
Social Insurance Institution 2006). According to the recent National Health and 
Nutrition Examination Survey (NHANES IV), about 29% of the adult population 
in the United States are hypertensive (>140/90 mmHg) or use antihypertensive 
medication (Hajjar and Kotchen 2003). The prevalence of hypertensive subjects 
in the United States has increased markedly; in the period from 1988 to 1994 
(NHANES III), 50 million people were hypertensive, and from 1999 to 2000 
(NHANES IV), as many as 65 million (Fields et al. 2004). With 140/90 mmHg 
as the criterion, 38% of the British adult population are hypertensive (Colhoun et 
al. 1998). 
15
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2.1.3 Hypertension and complications
There is a clear and independent relationship between blood pressure and 
cardiovascular disease (CVD) events. In recent studies, blood pressure variability has 
been shown to be a more important determinant of target organ damage than high 
blood pressure itself (Miao et al. 2006; Tatasciore et al. 2007). In the Framingham 
Heart Study, the risk ratio for coronary heart disease, stroke, peripheral artery 
disease and cardiac failure was about 2 to 3 times higher for hypertensive subjects 
than for normotensive subjects (Kannel 1996; Kannel et al. 2004). Hypertension 
was also associated with about a four-fold risk of atherothrombotic brain infarction 
in comparison with normotension (Kannel et al. 1996). Clinical trials have shown 
that in hypertensive subjects, lowering the blood pressure reduces the risk of 
cardiovascular diseases (Collins et al. 1990). Decreases in diastolic blood pressure 
of 5, 7.5 and 10 mmHg have been associated with at least 34%, 46% and 56% 
reductions, respectively, in the incidence of stroke, and with at least 21%, 29% and 
37% lower rates of coronary heart disease (MacMahon et al. 1990). On the other 
hand, a 20 mmHg increase in systolic blood pressure or a 10 mmHg increase in 
diastolic blood pressure doubles the risk of CVD in the blood pressure range of 
115/75 to 185/115 mmHg (Lewington et al. 2002). 
2.1.4 Regulation of blood pressure 
In normal conditions, the kidneys play a central role in the long-term regulation 
of blood pressure, while the central nervous system acts primarily as a short-
term regulator (Wyss and Carlson 1999) (Figure 1). The central nervous system 
modulates blood pressure by controlling cardiac output and peripheral resistance. 
The arterial baroreceptors located at the carotid arch and aortic sinuses and the 
cardiopulmonary baroreceptors are the two most important neural reflex arches 
involved in the regulation of blood pressure (Grassi et al. 1998; Stauss 2002). 
When blood pressure increases, the aortic baroreceptors acutely respond through 
parasympathetic activation and sympathetic inhibition. Baroreceptor activation 
decreases as blood pressure falls. When the afferent signals from baroreceptors 
enter the vasomotor centre in the medulla of the brain, the efferent signals are 
transferred via sympathetic nerves to the heart, vasculature and kidneys, and the 
signal is mediated by noradrenaline and adrenaline from the adrenal glands. Both 
of these catecholamines act by binding to adrenergic receptors (AR) classified as 
α1-AR, α2-AR or β-AR. The α2-AR family is known to affect vasodilation and 
vasoconstriction, the response being mediated by one of three receptor subtypes, 
all of which are present in the brain, kidney, heart and vasculature. Activation of 
α2A-ARs in the brain lowers blood pressure and plasma noradrenaline levels, while 
16
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activation of peripheral α2B-ARs causes sodium retention and vasoconstriction; 
activation of peripheral α2C-ARs causes cold-induced vasoconstriction (Kanagy 
2005). 
The kidneys respond to blood pressure changes by altering the excretion of 
sodium and water and thus controlling extracellular fluid volume (for review, 
see Lohmeier 2001). In normal conditions, when arterial pressure is elevated, the 
excretion of sodium and water increases until the blood volume is sufficiently 
reduced to return the arterial pressure to a normal level. In the long term, normal 
arterial pressure can be sustained by modulation of the pressure-natriuresis 
relationship. If the relationship between sodium excretion and arterial pressure is 
re-established and shifted to higher pressures, hypertension develops (for review, 
see Navar 1997). The renin-angiotensin-system (RAS) can modify the sensitivity 
of this pressure-natriuresis system. An increase in sodium intake suppresses the 
RAS, which enhances the kidneys’ ability to excrete sodium and water (for review, 
see Lohmeier 2001).
Figure 1. A schematic diagram of the blood pressure regulation system. 
17
R E V I E W  O F  T H E  L I T E R A T U R E
2.1.5 Treatment of hypertension
According to the ESH, the ESC, the JNC 7 and the WHO-ISH 2003, the main 
goal in the treatment of hypertension is to reduce the overall risk of cardiovascular 
morbidity and mortality or to reduce morbidity and mortality (Chobanian et al. 
2003; Whitworth 2003; Mancia et al. 2007). 
Lifestyle modification should be included for all patients, especially before 
antihypertensive medication is prescribed, and also for patients who require 
pharmacological treatment. Lifestyle modification includes weight reduction in 
obese and overweight subjects, dietary treatment, physical activity and moderation 
in alcohol consumption. The optimal body weight has been determined as a 
body mass index (BMI) of 18.5-24.9, which is the range for normal weight. The 
recommendation for physical activity is aerobic physical exercise 30 min per day 
on most days of the week, while the recommended alcohol intake is a maximum 
of two drinks (e.g. 720 ml of beer or 300 ml of wine) per day for men and one 
drink for women. Dietary treatment includes sodium restriction and a Dietary 
Approaches and Stop Hypertension (DASH)-type diet, containing lot of fruit, 
vegetables and low-fat dairy products (Appel et al. 1997). The DASH diet has 
been shown to be beneficial for blood pressure as it contains plenty of calcium and 
potassium (Chobanian et al. 2003). 
Pharmacological treatment is needed if the desired blood pressure values cannot 
be reached with lifestyle modification only. Blood pressure lowering medication 
reduces the risk of the complications of hypertension. To attain optimal blood 
pressure levels, some individuals need two or even more antihypertensive drugs. 
The individual’s risk profile and the presence or absence of target organ damage 
influences the choice of antihypertensive medication. The main classes of 
antihypertensive medication are diuretics, the target organ of which is the nephron, 
where they interfere with sodium reabsorption; ACE inhibitors, which inhibit 
ACE and therefore reduce the circulating levels of vasoconstrictor angiotensin II; 
angiotensin II receptor blockers, which lower blood pressure by blocking the AT1 
receptors; adrenergic receptor blockers (α-blockers, β-blockers): α-blockers cause a 
modest reduction in both peripheral resistance and cardiac output, β-blockers inhibit 
β-adrenergic activity and therefore reduce cardiac output and central sympathetic 
nervous outflow; and calcium channel blockers, which reduce intracellular calcium 
and therefore vasodilate vascular smooth muscle cells (Chobanian et al. 2003). 
Blood pressure management according to the JNC 7 is presented in Table 2. 
18
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Table 2. Blood pressure management according to the JNC 7 (Chobanian et al. 2003).
Blood pressure  
classification
SBP,  
mmHg
DBP, 
mmHg
Management
Normal <120 and <80 Encourage lifestyle modification
Prehypertension 120–139 or 80–89 Lifestyle modification, no 
antihypertensive medication  
if no compelling indication
Stage 1  
hypertension
140–159 or 90–99 Lifestyle modification and 
antihypertensive medication
Stage 2  
hypertension
≥160 or ≥100 Lifestyle modification and, for most 
patients, a combination of two 
antihypertensive medications
SBP = systolic blood pressure
DBP = diastolic blood pressure
2.1.6 Blood pressure measurement
Blood pressure measurement is challenging, since many different factors regulate 
blood pressure and the variability of blood pressure in repeated measurements is 
high. Factors such as measurement variation and biological variation (e.g. ambient, 
temperature, diurnal, etc.) can affect the accuracy of the measurements. Short-
term, daytime, diurnal and seasonal variations all influence blood pressure values. 
Short-term variability at rest is influenced by respiration and heart rate, and 
this variability is under the control of the autonomic nervous system. Daytime 
variability mainly depends on the degree of mental and physical activity. Diurnal 
variability causes an average fall of 15% in blood pressure during the night. Seasonal 
variation is considerable, usually with higher blood pressure values during the cold 
winter than the warm summer (Kristal-Boneh et al. 1996). Some factors can cause 
an acute increase in blood pressure levels including smoking, caffeine, alcohol, 
talking, physical activity and psychological factors such as anxiety and white-coat 
reaction (Reeves 1995). The intake of caffeine, for example, increases the plasma 
levels of catecholamines, particularly adrenaline (Nurminen et al. 1999). Smoking 
causes an acute increase in blood pressure and heart rate, which may be mediated 
via nicotine, which also causes catecholamine release (Primatesta et al. 2001).
Blood pressure can be measured in the office by a physician or nurse, at home 
by the subjects themselves, or by means of 24-hour ambulatory blood pressure 
measurement (ABPM). Different blood pressure measurement techniques can 
produce markedly different blood pressure values, the lowest being in ABPM and 
the highest in the office blood pressure measurement. This can result in over-
treatment of patients with antihypertensive medication (Campbell et al. 2005). 
In non-pharmacological studies, ABPM and home blood pressure measurements 
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appear to be useful, because they can detect even small changes in blood pressure 
values with less observer bias (Kawano 2002).
Office blood pressure measurement is commonly used for the diagnosis of 
hypertension (Erdine et al. 2006). This measurement has high variability, and all 
the factors that affect this measurement should therefore be carefully monitored 
in order to obtain reliable results. Measurements should be made using a validated 
and calibrated instrument with an appropriate-sized cuff. The patient should not 
drink coffee, smoke or eat for 30 minutes before the measurement. The patient 
should rest quietly and refrain from talking for at least five minutes before the 
measurement. The optimal situation is for the patient to be sitting in a chair with 
feet on the floor and an arm resting and supported at the heart level (Chobanian 
et al. 2003). At least two blood pressure measurements should be made during 
the office visit, and if the difference between the blood pressure values is over 
5 mmHg, the measurement should be repeated at least once in order to obtain 
reliable values. 
Home blood pressure measurement is a reliable way to monitor blood pressure values 
over a long period of time and to follow the effects of treatment. The same criteria 
for the instrument and the measurement situation applied in office blood pressure 
measurement settings are also relevant in home blood pressure measurement. 
Home blood pressure measurements give reliable information about the blood 
pressure values before antihypertensive medication, and during medication, they 
give information on the patient’s response to treatment (Chobanian et al. 2003).
24-hour ambulatory blood pressure registration (ABPM) is the most reliable 
method of measuring blood pressure and is regarded as the gold standard. 
It covers the circadian variation of blood pressure, giving information about 
the blood pressure values during the daytime and during the sleeping period. 
Compared with office and home blood pressure measurements, ABPM usually 
gives the lowest blood pressure values. In most people, blood pressure decreases 
by about 10 to 20% during the night; failure to do so ("nondippers") indicates 
an increased risk of cardiovascular diseases (Verdecchia 1995; Pierdomenico et al. 
1997). The actual measurements are usually taken every 15 min during the day 
and every 30 min during the night. This is a valuable method when the patient 
has suspected white-coat hypertension (Chobanian et al. 2003). The white-coat 
effect causes normotensive subjects to become hypertensive during a blood pressure 
measurement. It can be demonstrated using ABPM and sometimes also by using 
home blood pressure measurement (Beevers et al. 2001a). 
20
R E V I E W  O F  T H E  L I T E R A T U R E
2.2 RENIN-ANGIOTENSIN SYSTEM
The RAS is an important regulator of blood pressure and fluid and electrolyte 
balance (Brown and Vaughan 1998; Schmieder et al. 2007) (Figure 2). During the 
past few years, it has became evident that the RAS, which was originally regarded 
as a circulating hormone system, is also localised in tissues such as the brain, 
kidneys, adrenal cortex, heart, blood vessel wall and adipose tissue (for reviews, see 
Bader et al. 2001; Kramkowski et al. 2006). In the plasma, RAS is determined as 
a circulating hormone system, which regulates acute changes in the cardiovascular 
system. In tissues, the RAS regulates long-term changes. 
Figure 2. The renin-angiotensin system (Modified from Cheng et al. 2005). 
ACE angiotensin-converting enzyme
ACE2 angiotensin-converting enzyme 2
AT1 angiotensin II type 1 receptor
AT2 angiotensin II type 2 receptor
B1 bradykinin type 1 receptor
B2 bradykinin type 2 receptor
CAGE chymostatin-sensitive angiotensin II-generating enzyme
NEP neutral endopeptidase
t-PA tissue plasminogen activator
The rate-limiting enzyme in the RAS is renin, which is secreted by the 
juxtaglomerular cells in the kidney. The secretion of renin is regulated by renal 
perfusion pressure, sodium and sympathetic nerve activity (Hackenthal et al. 
1990). In the circulation, renin produces decapeptide angiotensin I (Ang I) from 
liver-derived angiotensinogen. ACE produces the very potent vasoconstrictor 
octapeptide angiotensin II (Ang II) from the weak vasoconstrictor Ang I. ACE is 
also called kininase II, and it catalyses the degradation of the vasodilator bradykinin. 
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Bradykinin is a nonapeptide formed from kininogens, which are mainly produced 
by hepatocytes. Bradykinin dilates blood vessels by stimulating the production of 
nitric oxide (NO), prostacyclin (PGI2), and endothelium-derived hyperpolarizing 
factor (EDHF) in the vascular endothelium (Su 2006). It also has direct relaxant 
effects on vascular smooth muscle via the B2 receptor (Berguer et al. 1993).
Ang II is a strong direct vasoconstrictor. It induces the release of aldosterone 
and therefore reduces the excretion of sodium and increases the blood pressure. 
It increases the activity of the sympathetic nervous system by augmenting 
noradrenaline release in the vasculature and causing vasoconstriction (for review, 
see Ardaillou 1997). Ang II also possesses pro-inflammatory properties, which has 
been emphasised in the development of complications, particularly those associated 
with hypertension (Mervaala et al. 2000). The effects of Ang II are mediated by the 
Ang II type 1 (AT1) and type 2 (AT2) receptors (for review, see de Gasparo et al. 
2000). AT1 receptors are localised in the vascular smooth muscle cells, brain, heart, 
kidneys and adrenal cortex. Most of the known cardiovascular effects of Ang II are 
mediated by AT1 receptors (Crowley et al. 2007). The activation of AT1 receptors 
activates phospholipase C and inhibits adenylate cyclase and thereby increases 
the levels of intracellular calcium in vascular smooth muscle cells (Orlov et al. 
1993; de Gasparo et al. 1995). Ang II causes vasoconstriction also by stimulating 
the formation of vasoconstrictor endothelin-1 (ET-1) in endothelial cells (Sung 
et al. 1994; Palatini 2001). AT2 receptors are expressed at low levels in the adult 
cardiovascular system, and it has been suggested that AT2 receptors antagonise 
the cardiovascular effects of Ang II mediated via AT1 receptors (for reviews, see 
Horiuchi et al. 1999; Burnier 2001). The AT2 receptor-induced vasodilation 
is mediated via cyclic guanosine monophosphate (cGMP), thus lowering the 
concentration of intracellular calcium (Savoia et al. 2006). 
Ang II mediated hypertension causes end-organ damage via increased blood 
pressure and also via the direct effects of Ang II. These effects are mediated 
by AT1 receptors and lead to end-organ damage in hypertension by promoting 
inflammation, fibrosis and vascular damage and by stimulating the production of 
reactive oxygen species. This damage can be reduced by AT1 receptor blockers and 
ACE inhibitors (Muller et al. 2000; Luft 2001; Crowley et al. 2006). 
There are also other angiotensin peptides, such as the degradation products 
of Ang II, including Angiotensin III (Ang III), Angiotensin IV (Ang IV) and 
Angiotensin (1-7) (Ang-1-7) (for review, see Kramkowski et al. 2006). These 
peptides, too, have biological effects, although Ang II is the major end product of 
the system. Ang III is formed via the activity of aminopeptidase A, Ang IV via the 
activity of aminopeptidases A and N, and Ang-(1-7) directly from Ang-(1-9) via the 
activity of prolylendopeptidase and carboxypeptidases (for review, see Ardaillou 
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1997). Ang III is a vasoconstrictor that shares most of the clinical properties of 
Ang II (Ardaillou 1997). It has been reported that Ang IV is a vasodilator and that 
its effect is mediated by activation of endothelial nitric oxide synthase (eNOS), 
although the findings are conflicting (Patel et al. 1998). The effects of Ang IV are 
suggested to be mediated through the AT4 receptor (Patel et al. 1998). Ang-(1-7) 
is an active peptide in the RAS and has opposite effects to Ang II. Ang-(1-7) is a 
vasodilator through stimulation of eNOS activation and NO production via the 
Mas receptor (Santos et al. 2003; Sampaio et al. 2007) (Figure 2).
In the tissues, Ang II formation (non-ACE) is also catalysed by chymase, 
cathepsin G, trypsin, chymostatin-sensitive angiotensin II-generating enzyme 
(CAGE), tissue plasminogen activator (t-PA), and tonin (Kokkonen et al. 1998; 
Belova 2000; Hu et al. 2003). It has been suggested that relatively high part of 
human Ang II may be formed in non-ACE pathways in tissues (Hollenberg et al. 
1998). 
2.3 VASCULAR ENDOTHELIUM
The vascular endothelium – the innermost cell layer covering all vessels – plays a 
significant role in cardiovascular homeostasis. Endothelium has the ability to sense 
changes in the mechanical, chemical and humoral environment and to react to 
these changes with compensatory correction of vascular tone and therefore arterial 
pressure. The endothelium inhibits platelet adhesion and aggregation, modulates 
blood flow and regulates vascular tone by releasing vasodilatory substances such 
as NO, PGI2 and EDHF as well as vasoconstrictor substances, such as endothelins 
(ET), thromboxane A2 (TXA2) and Ang II. Vasodilator and vasoconstrictor 
factors have an effect on vascular smooth muscle and thus regulate arterial tone 
(for reviews, see Vanhoutte and Mombouli 1996; Vapaatalo and Mervaala 2001; 
Behrendt and Ganz 2002; Vanhoutte et al. 2005) (Figure 3).
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Figure 3. Endothelium-derived vasorelaxing and vasoconstricting factors (Modified from 
McIntyre et al. 1999; Mombouli and Vanhoutte 1999) 
AA arachidonic acid ET endothelin
AC adenylate cyclase ETA endothelin-1 receptor A
ACE angiotensin converting enzyme GC guanylate cyclase
Ang I angiotensin I IP prostaglandin I2 receptor
Ang II angiotensin II IP3 inositol phosphate
AT1 angiotensin type 1 receptor L-Arg L-arginine
AT2 angiotensin type 2 receptor NO nitric oxide
ATP adenosine triphosphate NOS nitric oxide synthase
cAMP cyclic adenosine- 3’, 5’-monophosphate PC phospholipase C
cGMP cyclic guanosine- 3’, 5’-monophosphate PGI2 prostacyclin
COX-1 cyclooxygenase 1 PI phosphoinositol
ECE endothelin-converting enzyme TP thromboxane A2 / prostaglandin H2 receptor
EDHF endothelin-derived hyperpolarizing factor TXA2 thromboxane A2
2.3.1 Endothelial dysfunction
Endothelial dysfunction has been shown to be related to several cardiovascular 
diseases and cardiovascular risk factors such as hypertension and dyslipidaemia (for 
review, see Mombouli and Vanhoutte 1999). Endothelial dysfunction is characterised 
by a vasoconstrictive and prothrombotic state, meaning a decreased secretion of 
vasodilatory factors, an increased production and sensitivity to vasoconstrictors, 
and resistance of vascular smooth muscle to endothelial vasodilators. Dysfunction 
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is a consequence of an imbalance between relaxing and contracting factors, or 
growth promoting and inhibiting agents (for review, see Vapaatalo and Mervaala 
2001). Inflammation, lipoprotein oxidation or other oxidative stress reactions are 
factors affecting the development and maintenance of endothelial dysfunction. The 
endothelium plays a role in inflammatory processes, and the levels of C-reactive 
protein (CRP) have been shown to increase in endothelial dysfunction (Vita and 
Loscalzo 2002; Trepels et al. 2006). Theoretically, the clearest and most direct 
indicators of endothelial dysfunction are NO and its metabolites, as well as PGI2. 
In endothelial dysfunction, the NO synthesis is either impaired or inactivated by 
reactive oxygen species such as superoxide. It has been shown that the balance 
between NO and superoxide may be even more important than the absolute levels 
of either of these compounds alone (McIntyre et al. 1999). Thus, because NO 
is responsible for performing many important actions in the endothelium, such 
as causing vasodilation and antithrombotic effects, reduced NO formation and 
activity play a major role in endothelial dysfunction (Busse and Fleming 1996; 
Raij 2006). 
The risk factors for endothelial dysfunction include smoking, hypertension, 
hyperlipidaemia and diabetes. Reduced NO production is associated with all 
these risk factors (Bonetti et al. 2003). Aging has also been shown to be related 
to endothelial dysfunction (Galetta et al. 2006; Taddei et al. 2006). In addition 
to these traditional risk factors, there are more emerging risk factors, such as 
physical inactivity, obesity, renal failure and hyperhomocysteinaemia. Endothelial 
dysfunction can be either a cause or a consequence of several clinical conditions, 
and it has been suggested that the risk of developing endothelial dysfunction may 
increase with the number of risk factors present in a subject (Celermajer et al. 
1994). 
The treatment of endothelial dysfunction includes: reduction of cardiovascular 
risk factors using antihypertensive medication (e.g. ACE inhibitors, angiotensin II 
receptor blockers); cholesterol-lowering medication; estrogen replacement therapy 
in postmenopausal women; folic acid supplementation; reducing smoking and 
increasing physical activity (Vogel 1999; Hambrecht et al. 2000; Doshi et al. 2001; 
Vita and Keaney 2001; Taddei et al. 2002). The effect of ACE inhibitors is mainly 
based on their ability to improve the effect of bradykinin, which enhances the 
synthesis of nitric oxide in the endothelium. Induced or enhanced nitric oxide 
production, or added nitrates, can balance insufficient internal NO production 
(Taddei et al. 2002). ACE inhibitors and AT1 receptor antagonists may also 
prevent the age-related impairment of endothelium-dependent hyperpolarisation 
and relaxation mediated by endothelium-derived hyperpolarizing factor (EDHF) 
(Kansui et al. 2002). 
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2.3.2 Endothelium-derived vasodilatory factors
Nitric oxide
Furchgott and Zawadzki were the first to report the presence of a potent 
vasodilating substance, an endothelium-derived vasodilatory factor that was later 
shown to be NO (Furchgott and Zawadzki 1980; Ignarro et al. 1987). NO is 
an active component in the endothelium and is produced from L-arginine in 
endothelial cells by the enzyme eNOS after stimulation of muscarinic receptors 
by acetylcholine (Palmer et al. 1988, for review, see Stuehr 1999). Bradykinin also 
enhances the production of NO. Healthy endothelium constantly releases small 
amounts of NO.
NO is a very important vasodilator as it relaxes vascular smooth muscle. NO 
activates soluble guanylate cyclase in smooth muscle cells to produce cGMP, which 
causes smooth muscle relaxation by reducing intracellular calcium content (Feletou 
and Vanhoutte 2000; Behrendt and Ganz 2002). In addition to vasodilation, NO 
also regulates many physiological activities, including antithrombotic actions and 
immune cell activity (Gewaltig and Kojda 2002). These effects play a significant 
role in protecting against vascular injury (for review, see Hobbs et al. 1999). 
Inflammation impairs the expression and bioavailability of eNOS in experimental 
animals and in humans (for review, see Huang and Vita 2006). Oxidative stress 
decreases eNOS expression and the bioavailability of NO (Liao et al. 1995). 
Prostacyclin
PGI2 is a prostanoid which causes vasodilation and inhibits platelet aggregation. 
PGI2 is synthesised from arachidonic acid by cyclooxygenases 1 and 2 (COX-1 and 
COX-2). Most tissues express COX-1 constitutively, but COX-2 expression rises 
markedly mainly with cell activation, as in inflammation (Maclouf et al. 1998). 
Endothelial COX-2 produces mainly PGI2 in humans (FitzGerald and Patrono 2001; 
Rudic et al. 2005). Stimulation of prostaglandin I2 (IP) receptors activates adenylate 
cyclase in smooth muscle to produce cyclic adenosine monophosphate (cAMP) 
from adenosine triphosphate. cAMP decreases the concentration of intracellular 
calcium and causes vasodilation (Cohen and Vanhoutte 1995; FitzGerald and 
Patrono 2001). The synthesis of PGI2 in endothelial cells is activated by factors 
such as shear stress and hypoxia (for review, see Lüscher and Noll 1995).
Endothelium-derived hyperpolarizing factor 
Endothelium-dependent relaxation, which is resistant to the inhibition of nitric 
oxide synthase (NOS) and COX, is thought to be mediated via EDHF (Cohen and 
Vanhoutte 1995). EDHF mediates vasodilation by opening the Ca2+-regulated K+ 
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channels in the vascular smooth muscle cells and by inducing hyperpolarisation in 
smooth muscle membrane and thus inhibiting the inflow of calcium. Because of 
this, the concentration of intracellular calcium decreases, which causes relaxation 
in the smooth muscle (for reviews, see Feletou and Vanhoutte 1999; Feletou and 
Vanhoutte 2006). EDHF-mediated vasodilation plays an important role when 
NO production is impaired (Bauersachs et al. 1996). The chemical identity of 
EDHF has received a lot of attention, but no consensus has been reached. Several 
major candidates for EDHF have been proposed, such as K+, and arachidonic 
acid metabolites, such as epoxy-eicosatrienoic acid (for review, see Feletou and 
Vanhoutte 2006). One very recent candidate is C-type natriuretic peptide (Sandow 
and Tare 2007).  
2.3.3 Endothelium-derived vasoconstrictory factors
Angiotensin II
Angiotensin II has been described earlier in section 2.2. 
Endothelin-1
ETs, including ET-1, ET-2 and ET-3, are peptides with vasoconstrictor properties. 
ET-1, which comprises 21 amino acids, is a potent vasoconstrictor and its 
production is catalysed by endothelin-converting enzyme (ECE). Low shear 
stress, hypoxia, stretching the vascular wall and substances such as noradrenaline 
and Ang II increase the production of ET-1 (for review, see Lüscher and Noll 
1995). The vascular effects of ET-1 are mediated via the ETA receptor present in 
smooth-muscle cells, and via the ETB receptor present mainly in the endothelium 
(for reviews, see Rothermund and Paul 1998; Neylon 1999). The stimulation of 
ETA receptors activates phospolipase C and thereby increases the formation of 
inositol triphosphate, which increases the levels of intracellular calcium and causes 
vasoconstriction (Taddei et al. 2000) (Figure 3). 
Prostanoids
In addition to PGI2, the endothelium also produces vasoconstrictor prostanoids, 
such as prostaglandin H2 (PGH2), TXA2 and prostaglandin F2α (PGF2α). These 
vasoconstrictors are also produced by COX. Prostaglandin H2 is further converted 
to PGI2 by PGI2 synthase (Cohen 1995). 
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2.4 MINERALS AND BLOOD PRESSURE
Sodium is known to have harmful, blood pressure increasing effects, whereas 
calcium, potassium and magnesium are beneficial for blood pressure and have an 
important nutritional role in controlling blood pressure (for reviews, see Massey 
2001; Karppanen et al. 2005). 
2.4.1 Sodium 
The harmful effects of sodium on blood pressure are well known. It has been 
shown in epidemiological and clinical trials that high sodium intake increases 
blood pressure (for review, see Karppanen and Mervaala 2006). In the Intersalt 
study – the largest epidemiological study of its kind – elevated urinary sodium 
excretion as a marker of high sodium intake was associated with higher systolic and 
diastolic blood pressures (Intersalt Cooperative Research Group 1988; Elliott et al. 
1996). Several meta-analyses have shown that restricting sodium intake reduces 
blood pressure (Cutler et al. 1997; Graudal et al. 1998; He and MacGregor 2002; 
Geleijnse et al. 2003). In a meta-analysis of 17 trials with hypertensive subjects, a 
daily reduction of 6 g of salt reduced systolic blood pressure by about 7 mmHg and 
diastolic blood pressure by about 4 mmHg (He and MacGregor 2002). In a meta-
analysis of 40 trials, an average daily sodium reduction of 1.8 g reduced systolic 
blood pressure in hypertensive subjects by an average of 5.2 mmHg and diastolic 
blood pressure by 3.7 mmHg. In normotensive subjects, the mean reduction in 
systolic blood pressure was 1.3 mmHg and in diastolic blood pressure 1.1 mmHg 
(Geleijnse et al. 2003). 
In the second DASH trial, a reduction in sodium intake together with a 
diet rich in potassium, magnesium and calcium reduced systolic blood pressure 
compared to the control diet by 7.1 mmHg in normotensive subjects and by 11.5 
mmHg in hypertensive subjects (Sacks et al. 2001). 
2.4.2 Potassium 
Experimental, epidemiological and clinical trials show that potassium may have 
beneficial effects on blood pressure (for reviews, see Kotchen and McCarron 
1998; He and MacGregor 2001; He and MacGregor 2003). In a meta-analysis 
of 19 clinical trials (586 participants), oral potassium supplement (average 3.4 g 
daily) lowered systolic (-5.9 mmHg) and diastolic blood pressures (-3.4 mmHg) 
(Cappuccio and MacGregor 1991). In another meta-analysis of 33 studies (2609 
participants), an increased intake of potassium reduced systolic blood pressure by 
an average of 3.1 mmHg and diastolic blood pressure by 2 mmHg (Whelton et al. 
1997). The blood pressure lowering effect of potassium has been shown to be more 
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marked in hypertensive subjects. In a meta-analysis of 27 trials, a mean potassium 
intake of 1700 mg/d reduced systolic blood pressure in hypertensive subjects by an 
average 3.5 mmHg and diastolic blood pressure by 2.5 mmHg. In normotensive 
subjects, the mean reduction in systolic blood pressure was 1.0 mmHg and that in 
diastolic blood pressure 0.3 mmHg (Geleijnse et al. 2003).
The antihypertensive effect of potassium seems to be multifactorial (for reviews, 
see Treasure and Ploth 1983; Barri and Wingo 1997). The blood pressure lowering 
effect of potassium may be related to its diuretic properties. Potassium causes 
natriuresis and therefore lowers the extracellular fluid volume and reduces blood 
pressure (Young et al. 1976; Mervaala et al. 1992). Alternatively, potassium may also 
reduce the activity of the sympathetic nervous system, decrease renin production 
and the response to noradrenaline and Ang II (Campbell and Schmitz 1978; Fujita 
and Sato 1992; Vaskonen 2003). It has also been shown that potassium has effects 
on vascular responses, and it improves endothelium-dependent and -independent 
relaxation (Mervaala et al. 1994; for review, see Mervaala et al. 1998a). 
2.4.3 Calcium 
The antihypertensive activity of calcium has been clearly demonstrated in 
experimental studies (for review, see Hatton and McCarron 1994). In studies on 
SHR, calcium supplements have prevented the elevation of blood pressure (Pörsti 
et al. 1990; Pörsti et al. 1991; Mäkynen et al. 1995; Schleiffer and Gairard 1995). 
On the other hand, it has been observed that the removal of dietary calcium leads 
to a rise in blood pressure in experimental animals (Schleiffer and Gairard 1995).  
McCarron et al. were the first to report a connection between low intake 
of calcium and elevated blood pressure in humans (NHANES I) (McCarron et 
al. 1984). Several epidemiological studies demonstrating a connection between 
calcium intake and blood pressure have since been published (Cappuccio et al. 
1995; Narayan et al. 1998; Ruidavets et al. 2006; for review, see Geleijnse and 
Grobbee 2000). Beneficial effects of calcium on blood pressure have been also 
demonstrated in several clinical trials (Allender et al. 1996; Bucher et al. 1996; 
Griffith et al. 1999; van Mierlo et al. 2006). According to a recent meta-analysis 
of 40 studies, calcium supplementation (mean 1200 mg/d) reduced systolic blood 
pressure by about 2 mmHg and diastolic blood pressure by about 1 mmHg (van 
Mierlo et al. 2006). 
A diet rich in calcium, potassium, magnesium and fibre and poor in saturated 
fatty acids (e.g. diet rich in fruits, vegetables and low-fat dairy products) has been 
shown to reduce blood pressure in the DASH trial (Appel et al. 1997). With the 
DASH diet, the mean reduction in systolic blood pressure was -5.5 mmHg and in 
diastolic blood pressure -3.0 mmHg more than in the control group. In persons 
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with elevated blood pressure (140 mmHg/90 mmHg), the DASH diet produced 
a considerably higher reduction in blood pressure. Compared with the control 
group, the mean reduction in systolic blood pressure was about 11 mmHg greater 
and the mean reduction in diastolic blood pressure about 6 mmHg greater (Appel 
et al. 1997). 
Calcium may influence blood pressure by several mechanisms. One of the 
antihypertensive mechanisms is its natriuretic effect, which increases the excretion 
of salt (for reviews, see Hatton and McCarron 1994; Zemel 2001). Calcium plays an 
important role in controlling the tension of vascular smooth muscle. Extracellular 
calcium increases the stability of the cell membrane in vascular smooth muscle 
and reduces ion penetration through the cell membrane, which causes a decrease 
in intracellular calcium and vasodilation (Hatton et al. 1995). Potassium outflow 
is also reduced by a calcium-rich diet. Reduced cellular outflow of potassium is 
typical of calcium-induced cell membrane stabilisation (Furspan et al. 1989). The 
concentration of extracellular calcium may influence blood pressure by increasing 
the formation and release of endothelium-derived relaxing factors, such as NO and 
PGI2. Calcium has also been shown to reduce blood pressure by downregulating 
renal ACE (Pörsti et al. 2004). 
The effects of calcium on blood pressure may partly be mediated by calcium-
controlling hormones, including parathyroid hormone (PTH), 1.25(OH)2 vitamin 
D, and possibly calcitonin. Many hypertensive patients have elevated PTH levels, 
and increased dietary calcium and a concurrent reduction of sodium intake may 
therefore reduce blood pressure by reducing PTH levels. PTH influences blood 
pressure by increasing the formation and release of 1.25(OH)2 vitamin D, which 
independently increases blood pressure by increasing the amount of intracellular 
calcium in vascular smooth muscle. An increased concentration of intracellular 
calcium increases cellular contractility and raises blood pressure values (Zemel 
2001; Vaskonen 2003). Dietary calcium reduces the production of 1.25(OH)2 
vitamin D and therefore also the cellular intake of calcium. Calcium is also believed 
to influence the activity of the sympathetic nervous system. In experimental 
studies, the deprivation of dietary calcium led to an increase in noradrenaline and 
adrenaline levels, while calcium supplements were found to reduce the concentration 
of adrenaline in SHR (Hagihara et al. 1990; Scrogin et al. 1991). 
2.4.4 Magnesium 
Like potassium and calcium, magnesium has also beneficial effects on blood 
pressure, even though the results are somewhat controversial (for review, see Sontia 
and Touyz 2007).
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Experimental trials have shown that magnesium administration returned 
systolic blood pressure to normal or attenuated the development of hypertension 
(Mervaala et al. 1997; Soltani et al. 2007). Magnesium and potassium intake have 
been shown to reduce the harmful effects of sodium and to reduce blood pressure 
in SHR (Mervaala et al. 1992). On the other hand, magnesium deficiency has been 
shown to increase blood pressure in rats (Blache et al. 2006).
In a meta-analysis of 20 studies magnesium reduced systolic blood pressure by 
an average of -0.6 mmHg and diastolic blood pressure by -0.8 mmHg (Jee et al. 
2002). When the magnesium dose was increased, a dose-dependent reduction was 
seen in blood pressure values. In a ten-year follow-up study, magnesium intake was 
inversely associated with the risk of developing hypertension (Song et al. 2006). 
Some clinical studies support the claim that magnesium deficiency plays a role in 
the development of hypertension (Touyz et al. 1992; Resnick et al. 1997). 
It has been suggested that magnesium has beneficial effects on blood pressure 
via its vasodilatory properties. Magnesium acts as a calcium channel antagonist 
and stimulates the production of vasodilatory PGI2 and NO (for review, see Sontia 
and Touyz 2007).
2.5 BIOACTIVE PEPTIDES DERIVED  
FROM MILK PROTEINS
Milk proteins are an important source of bioactive peptides. Biologically active 
peptide fragments are formed when the milk proteins, whey and casein, are broken 
down by digestive enzymes in the gastrointestinal tract, by fermentation of milk 
with proteolytic starter culture or in proteolysis by enzymes derived from micro-
organisms (Teschemacher et al. 1997; Meisel 1998; Korhonen and Pihlanto 2003a; 
Korhonen and Pihlanto 2003b). Lactic acid bacteria and their proteolytic activity are 
well characterised. Lactic acid bacteria e.g. Lactobacillus helveticus, Lactococcus lactis 
and Lactobacillus delbrueckii ssp. bulgaricus are traditionally used in the production 
of fermented dairy products (Nakamura et al. 1995a; Nakamura et al. 1995b; 
Christensen et al. 1999). Over the last decade, many strains of lactic acid bacteria 
have been demonstrated to release bioactive peptides from milk proteins during 
milk fermentation (Nakamura et al. 1995a; Nakamura et al. 1995b; Christensen et 
al. 1999; FitzGerald and Murray 2006; Korhonen and Pihlanto 2006). Bioactive 
peptides have been shown to have many functions. These include their effects on 
the gastrointestinal system, including the regulation of digestive enzymes and the 
subsequent modulation of nutrient absorption from the intestine (Shimizu 2004). 
Peptides may also enhance immune cell functions and thereby affect the immune 
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system, while peptides with opioid activity affect the nervous system (for reviews, 
see Gill et al. 2000; teschemacher 2003; Korhonen and Pihlanto 2006). Peptides 
also influence the cardiovascular system. the most studied blood pressure lowering 
mechanism of milk peptides is aCe inhibition (nakamura et al. 1995a; nakamura 
et al. 1995b; takano t 1998; sipola et al. 2002a; for review, see Jauhiainen and 
Korpela 2007). Milk peptides may also lower blood pressure via other mechanisms, 
such as via opioid-like activities (Meisel and fitzGerald 2000). when the milk 
peptides are taken as a part of milk products, milk minerals might also have a role 
in lowering blood pressure. 
2.5.1 Peptides and blood pressure
Animal studies 
Acute effects 
Most animal studies on milk-derived peptides are acute (short-term) experiments, in 
which the effects on blood pressure are evaluated after a single oral administration. 
the milk casein-derived tripeptides ile-Pro-Pro and val-Pro-Pro (Figure 4) have 
been shown to reduce blood pressure in sHR after a single oral administration 
(nakamura et al. 1995b). a milk product fermented by Lactobacillus helveticus 
bacteria and Saccharomyces cerevisiae yeast containing ile-Pro-Pro and val-Pro-
Pro peptides reduced systolic blood pressure within six to eight hours of oral 
administration in sHR. the antihypertensive effect in this study was seen only 
with the hypertensive rat model, and not in normotensive wistar Kioto rats 
(nakamura et al. 1995b). it has been shown that whey protein-based α-lactorphin 
(tyr-Gly-Leu-Phe) lowers blood pressure dose-dependently after oral feeding 
in sHR and in normotensive wistar Kyoto rats. Blood pressure was measured 
by continuous radiotelemetric monitoring, and the decrease in blood pressure 
reached its maximum 50-100 minutes after administration and returned to the 
baseline level after 200 minutes (nurminen et al. 2000). Milk fermented with two 
Lactobacillus helveticus strains, Lactobacillus helveticus CHCC637 and Lactobacillus 
helveticus CHCC641 reduced mean arterial pressure by about 12 mmHg more 
than the control product in sHR (fuglsang et al. 2002). tyr-Pro dipeptide from 
a Lactobacillus helveticus CPn4 fermented yoghurt-like product also showed acute 
antihypertensive effects in sHR after a single oral dose when systolic blood pressure 
was measured by the tail-cuff method (Yamamoto et al. 1999). 
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Long-term effects
Ile-Pro-Pro and Val-Pro-Pro tripeptides have been shown to attenuate the 
development of hypertension in SHR after long-term, 12- and 13-week oral feeding 
(Sipola et al. 2001; Sipola et al. 2002a). At the end of the 12-week treatment period, 
systolic blood pressure was 17 mmHg lower in the group that received Lactobacillus 
helveticus LBK-16H fermented milk containing Ile-Pro-Pro and Val-Pro-Pro as 
compared to the control group, which was given water, and 12 mmHg lower in 
the group that was given the same tripeptides in water (Sipola et al. 2001). Similar 
results were obtained in the 13-week study; fermented milk containing Ile-Pro-Pro 
and Val-Pro-Pro tripeptides attenuated the development of hypertension (Sipola et 
al. 2002a). The results of the animal studies are summarised in Table 3.
Figure 4. Structural formulas of Ile-Pro-Pro and Val-Pro-Pro. 
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Clinical studies 
Lactobacillus helveticus fermented milk containing Ile-Pro-Pro and Val-Pro-Pro 
tripeptides has been shown to lower systolic and diastolic blood pressure in 
hypertensive subjects (Hata et al. 1996; Seppo et al. 2002; Mizushima et al. 2004). 
In two Japanese placebo-controlled studies on hypertensive subjects, Lactobacillus 
helveticus and Saccharomyces cerevisiae fermented milk reduced systolic and diastolic 
blood pressure during eight-week (Hata et al. 1996) and four-week (Mizushima et al. 
2004) interventions. In an eight-week placebo-controlled study on 17 hypertensive 
subjects, systolic and diastolic blood pressures decreased more (-10 mmHg and 
-7 mmHg respectively) in the group receiving Lactobacillus helveticus fermented 
milk containing Ile-Pro-Pro and Val-Pro-Pro tripeptides than in the placebo group 
receiving normal fermented milk (Seppo et al. 2002). 
Tablets containing Ile-Pro-Pro and Val-Pro-Pro tripeptides have also been 
shown to have a tendency to lower blood pressure in hypertensive subjects (Aihara 
et al. 2005; Mizuno et al. 2005). When comparing the studies with fermented milk 
containing Ile-Pro-Pro and Val-Pro-Pro tripeptides and the studies with tablets 
containing these tripeptides, it can be concluded that the p value between the 
groups has been reported in about half of the studies, and reported compared to 
the baseline level in the other half. The absolute blood pressure reductions with 
fermented milk and with tablets are about the same. 
In a very recent clinical trial with casein hydrolysate, systolic and diastolic 
blood pressure decreased more in the casein group than in the placebo group 
(Cadee et al. 2007). In a recent study of milk with whey peptides, the test product 
did not reduce systolic or diastolic blood pressure (Lee et al. 2007). Milk fermented 
by Lactobacillus casei and Lactococcus lactis and containing γ-aminobutyric acid 
reduced blood pressure during a 12-week treatment period. Systolic blood pressure 
decreased about 17 mmHg from baseline, which was significantly more than the 
reduction in the placebo group. Diastolic blood pressure in the fermented milk 
group did not differ from the placebo group (Inoue et al. 2003). In another 
eight-week study, systolic blood pressure was significantly lower in the group 
receiving yoghurt fermented with two strains of Streptococcus thermophilus and 
two strains of Lactobacillus acidophilus as compared to the group which received 
yoghurt fermented with two strains of Streptococcus thermophilus and one strain 
of Lactobacillus rhamnosus. A similar lowering of systolic blood pressure was 
also obtained in a group which received yoghurt fermented with two strains of 
Streptococcus thermophilus and one strain of Enterococcus faecium (Agerholm-Larsen 
et al. 2000). Almost all the clinical trials with bioactive milk peptides involve active 
and placebo groups. The results of clinical studies are presented in Table 4.
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2.5.2 Blood pressure lowering mechanisms 
Angiotensin-converting enzyme inhibition
the most widely studied mechanism by which milk-derived peptides can reduce 
blood pressure is aCe inhibition (for reviews, see fitzGerald and Meisel 2000; 
Kitts and weiler 2003; López-fandiño et al. 2006). 
several antihypertensive peptides that inhibit aCe have been identified from 
milk products, and the aCe inhibitory activity and iC50 values (the concentrations 
at which aCe activity in vitro is inhibited by 50%) of some of these peptides have 
been determined in vitro (Karaki et al. 1990; nakamura et al. 1995b; Maeno et al. 
1996; Yamamoto et al. 1999). the iC50 values of the casein-derived tripeptides ile-
Pro-Pro and val-Pro-Pro have been found to be 5 μM and 9 μM, respectively. the 
aCe inhibitory activity of these peptides is, however, much weaker than that of 
aCe inhibitor medication (Mullally et al. 1996), and it cannot always be directly 
related to the blood pressure lowering effects in vivo. the relationship between 
aCe inhibitory peptides and the structural activity has not been confirmed. 
However, some general features have been found. aCe inhibitory peptides usually 
contain 2-12 amino acids (Robert et al. 2004), and hydrophobic amino acids at the 
C-terminal position, as in proline, could be the most likely to have aCe inhibitory 
properties (ondetti and Cushman 1984). 
the aCe inhibitory activity of ile-Pro-Pro and val-Pro-Pro has been shown 
in vitro (nakamura et al. 1995a), and evidence for aCe inhibition has also been 
demonstrated in vivo. Lactobacillus helveticus fermented milk containing ile-Pro-Pro 
and val-Pro-Pro raised plasma renin activity in sHR during long-term treatment 
(sipola et al. 2002a). aCe activity in the aorta of sHR was reduced after a single 
oral administration and after long-term treatment with Lactobacillus helveticus and 
Saccharomyces cerevisiae fermented milk containing ile-Pro-Pro and val-Pro-Pro 
tripeptides (nakamura et al. 1995b; nakamura et al. 1996). aCe activity has also 
been studied in a clinical trial, but no clear aCe inhibition was found. in a study 
by Mizushima et al., the serum levels of ang i and ang ii were measured but there 
was no significant change in the ang i/ang ii ratio at four weeks (Mizushima et al. 
2004). Milk-derived peptides such as α-lactorphin and β-lactorphin, which have 
antihypertensive effects via other mechanisms than aCe inhibition, have also been 
investigated (nurminen et al. 2000). 
in addition to local aCe, ang ii formation can also be related to other enzymes 
like CaGe, cathepsin G, chymase, neutral endopeptidase (neP), t-Pa and tonin 
(Figure 2.). these enzymes may also play a role when the blood pressure lowering 
effects of biologically active peptides are considered. 
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Other possible mechanisms
several milk peptides have opioid-like activity (for reviews, see antila et al. 1991; 
teschemacher and Koch 1991; teschemacher et al. 1997). opioid-like activity has 
been discovered in many peptide fragments from casein, and the first opioid milk 
peptide agonist to be characterised was derived from β-casein (β-casomorphin). 
the peptides with opioid-like activity derived from α-casein are called α-exorphins, 
while those from κ-casein are called casoxins. opioid peptides can also be derived 
from the whey proteins α-lactalbumin and β-lactoglobulins. α-Lactorphin, found 
in α-lactalbumin, has been shown to lower blood pressure in sHR. Because the 
antihypertensive effect of α-lactorphin was completely prevented by the opioid 
receptor antagonist naloxone, it has been proposed that the antihypertensive effect 
may be mediated via opioid receptors (nurminen et al. 2000). 
Milk-derived caseinophosphopeptides have been shown to increase the 
solubility of calcium and to enhance its absorption (tsuchita et al. 2001). However, 
recent clinical studies suggest that the enhancement of calcium absorption by 
caseinophosphopeptides is so minor that is unlikely to have any clinical relevance 
(Lopez-Huertas et al. 2006; teucher et al. 2006). Bioactive peptides may also 
have beneficial cardiovascular effects via their antithrombotic effects. the 
peptides that inhibit the aggregation of blood platelets have been identified as 
caseinomacropeptides (for review, see fiat et al. 1993). 
2.5.3 Peptides and vascular function
Milk-derived peptides might have beneficial effects on blood pressure by improving 
vascular function. However, the effect has been shown only in in vitro studies. 
α-lactorphin and β-lactorphin derived from whey protein have been shown to 
improve arterial function in sHR in vitro (sipola et al. 2002b). fermented milk 
containing ile-Pro-Pro and val-Pro-Pro tripeptides has also been shown to improve 
sodium nitroprusside-induced endothelium-independent vasorelaxation in sHR in 
vitro (sipola 2002). this effect of ile-Pro-Pro and val-Pro-Pro might be related 
to these peptides' weak aCe-inhibitory activity, because in many studies, aCe 
inhibitors have been shown to reduce arterial stiffness in rats and in humans 
(Chillon et al. 1992; ahimastos et al. 2005). Casomokinin L has also been shown 
to relax mesenteric arteries in an experimental trial (fujita et al. 1996), and the 
dipeptide val-tyr has been reported to cause vascular relaxation in the aorta in 
vitro in sHR (tanaka et al. 2006). Bovine lactoferrin, on the other hand, has been 
shown to cause hypotension in rats via an endothelium-dependent vasodilation 
that is strongly mediated by no production (Hayashida et al. 2004). 
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2.5.4 Kinetics of peptides
the kinetics of milk-derived bioactive peptides are not well known. However, the 
kinetics of peptides are a central issue in the evaluation of their effects and efficacy. 
Milk peptides which are not degraded in proteolysis can theoretically be absorbed 
intact. it has been suggested that dipeptides and tripeptides are absorbed in the 
intestine (Masuda et al. 1996; satake et al. 2002). furthermore, it has also been 
reported that tripeptides containing a C-terminal proline-proline bond are usually 
resistant to human proteolytic enzymes (for review, see vanhoof et al. 1995). val-
Pro-Pro has been reported to be transported via the Caco-2 cell monolayer by 
paracellular diffusion (satake et al. 2002). in a recent study, the absorption of 
ile-Pro-Pro was evaluated by measuring the plasma concentrations of peptides in 
humans before and after the intake of tripeptides. the plasma concentrations of 
ile-Pro-Pro increased, and the net area under the curve (auC) for plasma ile-Pro-
Pro during the 120-minute follow-up after consumption of lactotripeptide enriched 
yoghurt (20.4 mg ile-Pro-Pro, 20 mg val-Pro-Pro, 16.5 mg Leu-Pro-Pro) in the 
fasted state was 2.2-fold compared to the placebo values. it was therefore suggested 
that ile-Pro-Pro was absorbed through the intestine and reached the circulation 
undegraded (foltz et al. 2007). the absorption of longer peptides has also been 
studied. the aCe-inhibitory peptide lactokinin (ala-Leu-Pro-Met-His-ile-arg) 
has been found to be transported intact through the Caco-2 Bbe monolayer in 
vitro. ala-Leu-Pro-Met-His-ile-arg was clearly shown to be present in mucosal 
compartment when analysed with high performance liquid chromatography and 
mass spectrometry, but in serosal compartment it was detected only with mass 
spectrometry (vermeirssen et al. 2002). 
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Nutritional factors have been shown to have important role in the prevention 
and treatment of hypertension. Earlier studies have shown that minerals, such 
as sodium, potassium, calcium and magnesium have a role in blood pressure 
regulation. Recent experimental and clinical studies have suggested that the 
bioactive peptides Ile-Pro-Pro and Val-Pro-Pro derived from milk have beneficial 
effects on blood pressure. However, the antihypertensive mechanisms, the kinetics, 
the long-term blood pressure lowering effects and the effects of vascular function 
of Ile-Pro-Pro and Val-Pro-Pro are not well known. The present study investigated 
these properties of the tripeptides Ile-Pro-Pro and Val-Pro-Pro in more detail by 
using experimental animal models and hypertensive subjects.
The specific aims were: 
1. Experimental: To investigate the antihypertensive mechanisms of Ile-Pro-Pro 
and Val-Pro-Pro and to evaluate the absorption, tissue distribution and excretion 
of Ile-Pro-Pro (I, II). 
2. Clinical: To verify the long-term blood pressure lowering effects of peptide milk 
containing Ile-Pro-Pro and Val-Pro-Pro tripeptides using different blood pressure 
measurement techniques and to evaluate the effects of a peptide milk containing 
Ile-Pro-Pro and Val-Pro-Pro on arterial stiffness (III, IV, V, VI).  
3  A ims of the Study
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4.1  EXPERIMENTAL ANIMALS  
AND STUDY DESIGNS
Male spontaneously hypertensive rats (SHR; Harlan Sprague-Dawley, Indianapolis, 
IN, USA) were used in Study I and male Sprague-Dawley rats (Charles River 
Laboratories Ltd, Edinburgh, UK) in Study II. In unpublished data, the male double 
transgenic rats (dTGR) harbouring human renin and human angiotensinogen 
genes (Biotechnology and Animal Breeding Division, Füllinsgdorf, Switzerland) 
were used (Jauhiainen et al. unpublished data). The rats were housed five to a cage 
(Study I, Jauhiainen et al. unpublished data) or in individual cages (Study II) in a 
standard experimental animal laboratory with automatic control of light cycles and 
temperature (light hours were 6.00/7.00 a.m. to 6.00/7.00 p.m., room temperature 
18–24°C and humidity 40–60%). A standard laboratory diet of known formulation 
(SDS Rat and Mouse Maintenance Diet No. 1, 1 Stepfield, Witham, Essex, UK 
or 2018, Harlan Nederland, Horst, The Netherlands) and drinking fluid (tap 
water, mineral water, peptide water, peptide+mineral water or peptide milk) were 
available ad libitum. The consumption of feed was monitored weekly and drinking 
fluids daily throughout the study. The blood pressure was measured weekly by 
the same trained person with tail-cuff blood pressure measurement (IITC Life 
Science, Woodland Hills, CA, USA) (Study I, Jauhiainen et al. unpublished data). 
In all experimental studies, the rats were housed in metabolic cages. In Study I, 
24-hour housing in metabolic cages took place at the beginning and end of the 
treatment period, and in Study II, 24-hour and 48-hour housing followed single 
administration of the peptide. The blood samples were taken at the end of the 
4  Mater ials and 
Methods
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treatment period (Study I, Jauhiainen et al. unpublished data) or at scheduled times 
up to 24 or 48 h post dosing (Study II). 
The study protocol was approved by the Animal Experimentation Committee 
of the Institute of Biomedicine, Helsinki, Finland (Study I, Jauhiainen et al. 
unpublished data). Study II was performed under Home Office licence PPL 60/2687, 
Toxicology of Medical and Veterinary Materials, Edinburgh, UK (Table 5). 
Table 5. Experimental animals.
Strain Number at the 
beginning of  
the treatment
Treatment  
period
Weight at 
the end of 
the treatment 
Age
Study I SHR 50 9 weeks 330–350 g 8–17 
weeks
Study II Sprague-
Dawley
11 single 
administration
230–280 g 7–8 
weeks
Unpublished 
data
dTGR 35 3 weeks 220–240 g 4–7 
weeks
4.2 SUBJECTS AND STUDY DESIGNS
Study III
The long-term blood pressure lowering effects of Lactobacillus helveticus fermented 
milk containing Ile-Pro-Pro and Val-Pro-Pro (peptide milk, peptides 5 mg/d) 
were investigated in Study III. Thirty-nine hypertensive volunteers with a mean 
systolic blood pressure of ≥140 mmHg and/or mean diastolic blood pressure of ≥90 
mmHg in office blood pressure measurements were included in the randomised, 
placebo-controlled, double-blind study. The subjects were randomly allocated to 
two groups to receive either the peptide milk containing Ile-Pro-Pro and Val-Pro-
Pro or a placebo drink for 21 weeks after a two-week run-in period (Figure 5). 
Separate randomisation lists were used for those who were taking antihypertensive 
medication and those who were not. The blood pressure and heart rate were 
measured at home using a fully automatic blood pressure recorder (Omron M4, 
Omron Matsusaka Co Ltd, Matsusaka, Japan). Daily use of the study products 
was recorded by means of a pre-tested postal questionnaire. The subjects were also 
asked to report if they had experienced any adverse effects. 
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Figure 5. Study design in Study III.
Study IV
The effects of Lactobacillus helveticus fermented milk containing high concentrations 
of the tripeptides Ile-Pro-Pro and Val-Pro-Pro (peptide milk, peptides 50 mg/d) 
on blood pressure, together with any adverse effects, were examined in Study IV. 
Ninety-four hypertensive subjects with a mean systolic blood pressure of 140–180 
mmHg and a diastolic blood pressure of 90–110 mmHg in office blood pressure 
measurements participated in this randomised, placebo-controlled, double-blind 
study. Exclusion criteria were blood pressure lowering medication, unstable 
coronary artery disease, diabetes mellitus, malignant diseases, alcohol abuse, milk 
allergy and pregnancy. The subjects were randomly allocated to two treatment 
groups (peptide milk group and placebo group) after a four-week run-in period. 
This was followed by a ten-week intervention period and a four-week follow-up 
period (Figure 6 ). Blood pressure was measured at the beginning and end of the 
ten-week intervention period with an automatic 24-hour blood pressure recorder 
(SpaceLab ABP 90207, Redmont, CA, USA). Subjects were asked to fill in a form 
about their daily use of the test products. The subjects were also asked, at every 
visit, whether they had experienced any adverse effects. 
Figure 6. Study design in Studies IV and V.
Peptide milk group
Run-in 2 weeks
Placebo group
21-week intervention,  
home blood pressure measurement
Peptide milk group
Run-in 4 weeks
#* *#
Follow-up 4 weeks
Placebo group
10-week intervention
* 24-hour ambulatory blood pressure measurement
# Blood samples
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Study V
Study V was analysed from the data of Study IV, so the study design (Figure 6.) 
and the inclusion criteria for subjects in Study V were the same as in Study IV. The 
analyses of ambulatory arterial stiffness index (AASI) included 94 subjects who 
participated in the 24-hour ABPM.
Study VI
The effect of Lactobacillus helveticus fermented milk containing Ile-Pro-Pro and 
Val-Pro-Pro tripeptides (peptide milk) on vascular function was investigated in 
Study VI. Subjects with a systolic blood pressure of 140 to 155 mmHg and diastolic 
blood pressure of 85 to 99 mmHg in office and in 24-hour ABPM were included. 
Eighty-nine subjects participated in this double-blind, randomised, placebo-
controlled study. After a four-week run-in period, the subjects were randomly 
allocated to an active group that received bioactive peptides or to a placebo 
group. During the first 12-week intervention period, the peptide dose was 5 mg/d 
(peptide milk 1); during the second 12-week intervention period, the peptide dose 
was 50 mg/d (peptide milk 2) in the peptide milk group. After the two 12-week 
intervention periods, there was a four-week follow-up period (Figure 7). Arterial 
stiffness and endothelial function testing was performed at the beginning and end 
of the intervention periods with pulse wave analysis (PWA) using a SphygmoCor 
(SphygmoCor, AtCor Medical, Sydney, Australia) device. Blood pressure was 
recorded at the same time points twice in the lying position (Omron M4, Omron 
Matsusaka Co. Ltd., Kyoto, Japan]). Subjects were asked to fill in a form about 
their daily use of the test products and to report any adverse effects over the whole 
study period. Subjects were also asked at every study visit about adverse effects. 
Demographic characteristics of the study subjects are presented in Table 6.
Figure 7. Study design in Study VI. 
Peptide milk 1 Peptide milk 2
Run-in 4 weeks
#* *#
*#
Follow-up 4 weeks
Placebo 2Placebo 1
12 weeks 12 weeks
* Pulse wave analysis
# Blood samples
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Ethics
The clinical studies were conducted according to the Helsinki Declaration and 
Good Clinical Practice. The Ethics Committee of the Department of Medicine, 
Tampere University Central Hospital (Studies IV and V), and the Ethics Committee 
of the Joint Authority for the Hospital District of Helsinki and Uusimaa (Study 
VI) approved the study protocols. All the subjects received both written and oral 
information regarding the trial and gave their written consent. 
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4.3 MEASUREMENT OF  
BLOOD PRESSURE
Experimental studies 
4.3.1  Tail-cuff method (Study I,  
Jauhiainen et al. unpublished data)
In the studies with SHR and dTGR the effect of different treatments on systolic 
blood pressure was investigated using a tail-cuff blood pressure analyser (IITC Life 
Science, Woodland Hills, CA, USA). The systolic blood pressure and heart rate 
of each rat were monitored weekly. Before measurement, the rats were warmed at 
+32°C for 15 minutes to improve detection of the pulse of the tail artery. The systolic 
blood pressure value was defined as the mean of three successful measurements 
without signal disturbances.
Clinical studies 
4.3.2 Office blood pressure measurement (Study VI)
Office blood pressure was measured using a fully automatic blood pressure 
recorder (Omron M4, Omron Matsusaka Co. Ltd., Kyoto, Japan). Blood pressure 
was measured after a 15-minute rest in the lying position in the morning (8–10 
a.m.). If the difference between the first two systolic blood pressure measurements 
was more than 5 mmHg, further measurements were made. If more than two 
measurements were made, those measurements between which the difference in 
systolic blood pressure was less than 5 mmHg were included in the analysis. The 
subjects were asked not to eat or drink coffee for 12 hours before the blood pressure 
measurement and to avoid heavy exercise a day before the measurement. 
4.3.3 Home blood pressure measurement (Study III)
In the long-term clinical trial, blood pressure on the first study visit was measured 
from the left arm by a nurse using a fully automatic blood pressure recorder (Omron 
M4, Omron Matsusaka Co. Ltd., Kyoto, Japan). Blood pressure was measured in a 
sitting position after a 10-minute rest. At the second visit, the subjects were taught 
how to measure their own blood pressure, following which they measured their 
own blood pressure at home on the same weekday every week, in the morning, 
one hour after waking. The subjects were asked not to eat, smoke, exercise or take 
antihypertensive medication before the blood pressure measurement. The inclusion 
of blood pressure values in the analysis was determined using the same criteria as 
described earlier (see 4.3.2).
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4.3.4 Twenty-four-hour ambulatory blood  
pressure measurement (Study IV)
In Study IV blood pressure was measured at the beginning and end of the ten-week 
intervention period with an automatic 24-hour blood pressure recorder (SpaceLab 
ABP 90207, Redmont, CA, USA). Blood pressure was measured four times an 
hour during the daytime and twice an hour during the night. During the day 
the measurements were made after a signal and during the night time silently. 
The measurement was accepted if at least 80% of the readings were successful, 
otherwise the measurement was repeated.
4.4 ARTERIAL RESPONSES
Experimental studies 
4.4.1 Arterial preparations and responses (Study I)
Immediately after decapitation, the mesenteric artery and abdominal aorta of 
the SHR were cleaned of adherent connective tissue. The mesenteric artery 
and aorta rings (3 mm long) were placed between stainless steel hooks and 
suspended in an organ bath chamber in Krebs-Ringer buffer (pH 7.4). The rings 
were equilibrated for 45 minutes at + 37ºC with a resting tension of 1.0 g. The 
force of contraction was recorded with a polygraph (FTO3 transducer, Model 
7P122E Polygraph, Grass Instrument Co, Quincy, MA, USA). The presence of 
functional endothelium was confirmed by observing the relaxation response to 
acetylcholine after noradrenaline contraction in the arterial rings. The cumulative 
relaxation responses to acetylcholine (endothelium-dependent relaxation) and to 
sodium nitroprusside (endothelium-independent relaxation) were measured after 
noradrenaline precontraction. 
4.4.2 ACE-inhibitory activity (Study I, Jauhiainen et al. 
unpublished data)
The ACE-inhibitory activity of Ile-Pro-Pro and Val-Pro-Pro in vitro was measured 
by preincubating the arterial rings from normotensive Sprague-Dawley rats with 
tripeptides Ile-Pro-Pro and Val-Pro-Pro for 10 minutes and measuring the response 
to a single administration of Ang I (1 µM)(Jauhiainen et al. unpublished data). 
The contraction response to Ang I (0.1 µM) in the mesenteric artery rings was 
also measured in Study I. The force of contraction was recorded with a polygraph 
(FTO3 transducer, Model 7P122E Polygraph, Grass Instrument Co, Quincy, MA, 
USA).
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Clinical studies 
4.4.3 Ambulatory arterial stiffness index (Study V)
The AASI was calculated from the ambulatory blood pressure readings of Study 
IV. The regression slope of diastolic blood pressure on systolic blood pressure was 
computed from the individual 24-hour blood pressure readings taken at 30-minute 
intervals from 8 a.m. to 10 p.m. and at 60-minute intervals from 10 p.m. to 8 a.m. 
AASI was defined as 1 minus the regression slope, as described by Li et al. (Li et 
al. 2006b).
4.4.4 Pulse wave analysis (Study VI)
Arterial stiffness was assessed by measuring of PWA using a SphygmoCor 
(SphygmoCor; AtCor Medical, Sydney, Australia) device. Blood pressure was 
recorded twice in the dominant arm in the lying position using a validated 
technique (Omron M4, Omron Matsusaka Co. Ltd., Kyoto, Japan). Radial artery 
waveforms were recorded with a high-fidelity micromanometer (SPC-301, Millar 
Instruments, Houston, TX, USA) from the wrist. The aortic augmentation index 
(AIx) was calculated as the augmentation of aortic systolic blood pressure by 
the reflected pulse wave, expressed as a percentage of the aortic pulse pressure. 
Because AIx is influenced by heart rate, AIx adjusted to a heart rate of 75 beats/
min calculated by the software was used in the analysis (Wilkinson et al. 2000). 
The subjects were examined after a 12-hour fast and were asked to avoid alcohol 
consumption and exercise on the day prior to the measurements. The examinations 
were conducted in a quiet, temperature-controlled room after a 15-minute rest. 
The time to return of the reflected wave (Tr) was calculated as the time from 
the beginning of the derived aortic systolic pressure waveform to the inflection 
point. Tr can be used as a substitute for pulse wave velocity (a higher pulse wave 
velocity will result in a shorter Tr) (London et al. 1992). Vascular endothelial 
function was studied using the PWA method developed by Wilkinson et al. 
(Wilkinson et al. 2002a). This method investigates the effects of nitroglycerin 
(endothelium-independent relaxation) (500 µg tablet, Nitro, Orion, Espoo, Finland) 
and salbutamol (endothelium-dependent relaxation) (2x200 µg inhalations of 
salbutamol, Ventoline Evohaler®, GlaxoSmithKline, London, UK) on the AIx. 
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4.5 COLLECTION OF SAMPLES
Experimental studies 
Blood samples
In animal experiments the rats were rendered unconscious with CO2/O2 (95%/5%) 
(AGA, Riihimäki, Finland). Blood samples were collected after decapitation 
(Study I, Jauhiainen et al. unpublished data) or by cardiac puncture (Study II). 
Blood samples were analysed immediately (Study II) and/or taken into chilled 
tubes, centrifuged (3000 rpm, 20 minutes, +4ºC) and stored at -80 ºC until the 
biochemical determinations (Study I, II).  
Tissues
In Study I the kidney and aorta were removed and snap-frozen in liquid nitrogen 
and stored at -80ºC until the determinations. In the unpublished data, the heart 
and kidneys were removed and weighed, and the ratios to body weight were 
calculated. For morphological analysis, the renal samples were fixed in 4% buffered 
paraformaldehyde, dehydrated in graded alcohol, and embedded in paraffin. 
Sections of 2–3 µm were cut with a microtome and placed on glass. The sections 
were deparaffinised and rehydrated before staining with Masson’s trichrome. 
Renal damage was analysed in a blind fashion and divided into four scores of 0–4 
(0=normal and 4=severe damage) (Jauhiainen et al. unpublished data). In Study II, 
the tissues were collected and homogenised and duplicate samples were prepared 
for the determination of radioactivity levels. 
Metabolic cages
Urine was collected using metabolic cages (24 h or 48 h) (Studies I, II and Jauhiainen 
et al. unpublished data). Urine volumes were measured and the samples were stored 
at -80ºC until biochemical determinations. In Study II, faeces were also collected 
and the levels of radioactivity were determined. In Study I, the consumption of 
feed and drinking fluids was measured and the intake of minerals and peptides 
was calculated.
Clinical studies 
In clinical studies (Studies IV and VI), blood samples were taken from the cubital 
vein at the beginning and end of the intervention phase after an overnight (12-
hour) fast. The blood samples were stored at -80ºC until the determination of 
serum total, LDL and HDL cholesterol and triglycerides, ACE activity, C-reactive 
protein and safety markers (blood cell count, serum creatinine, urate and gamma 
glutamyl transferase).
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4.6 BIOCHEMICAL DETERMINATIONS
4.6.1 Peptide and mineral concentrations (Studies I, III, IV, VI)
The peptide concentrations of the fermented milk products were determined by the 
method of Masuda et al. (Masuda et al. 1996). The peptide fraction was obtained by 
gel filtration chromatography (Superdex Peptide HR 10/30, Amersham Pharmacia 
Biotech, Bucks, UK) and analysed by reversed-phase High Performance Liquid 
Chromatography (HPLC) (Novapak C18, Waters Alliance HPLC, Milford, 
MA, USA). Minerals were determined using an Elan 6100 ICP-MS (Inductively 
Coupled Plasma Mass Spectrometer) (PerkinElmer SCIEX, Shelton, USA). For 
the calcium analysis, the samples were weighed and transferred to a muffle furnace 
(NaberthermN11, Bremen, Germany) and maintained at +550°C overnight until a 
white ash was obtained. The samples were cooled and dissolved in nitric acid and 
analysed by ICP-MS. 
4.6.2 Plasma and serum analyses (Studies I, IV, VI)
In the experimental study, plasma renin activity (PRA) was measured using a 
radioimmunoassay of Ang I (Medix Angiotensin I test®, Medix Biochemica, 
Kauniainen, Finland).
In the clinical studies serum total cholesterol, HDL cholesterol and triglycerides 
were measured enzymatically. LDL cholesterol was calculated using the 
Friedewald equation (Friedewald et al. 1972). Serum ACE activity was determined 
spectrophotometrically using the artificial substrate method (Groff et al. 1993), 
and sensitive C-reactive protein was determined from serum using a turbidimetric 
immunoassay (Wako Chemicals, Neuss, Germany).
4.6.3 Urine analyses (Study I)
Urinary sodium and potassium were determined by flame emission spectrometry 
(Burtis et al. 1975) and calcium and magnesium by flame atomic absorption 
spectrometry (Cali et al. 1973). Urinary creatinine was determined enzymatically 
and phosphate by spectrometry. Urinary nitrate and nitrite were determined using 
the Griess reaction (Green et al. 1982). 
4.6.4 Radioactivity analyses (Study II)
The samples (whole blood, faeces and tissue) were subjected to liquid scintillation 
counting using a Packard TR 2100 Liquid Scintillation Analyser (PerkinElmer Life 
and Analytical Sciences, Inc., Boston, MA, USA) with automatic quench correction 
by an external method. All samples analysed by liquid scintillation counting for this 
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study were above the reliable quantification limits. Plasma samples were analysed 
by means of HPLC (HP 1100 Series, Agilent Technologies, Inc., Santa Clara, CA, 
USA) and by size-exclusion chromatography. Plasma samples were injected directly 
onto the column alongside the protein molecular weight standard solutions and 
the Ile-Pro-[14C]Pro standard solution. The molecular mass of each of the resolved 
radioactive peaks was estimated using the calibration curve. Plasma samples were 
taken for further analyses by reversed-phase HPLC to identify the radioactive 
compounds present. Liquid chromatography-mass spectrometry (LC-MS) analysis 
was then performed on the reference standards and isolated peaks of interest to 
confirm that Ile-Pro-Pro was present in the sample.
4.6.5 Plasma protein binding properties (Study II)
The plasma protein binding properties of Ile-Pro-Pro and Pro-Pro were examined 
in vitro by incubating the peptides with human serum albumin and with human 
plasma. The incubations were performed at +37°C for 30 minutes in 4% human 
serum albumin (Sigma-Aldrich, St. Louis, MO, USA ) and in plasma with a 
peptide concentration of 10 µM Ile-Pro-Pro or 10 µM Pro-Pro. After incubation, 
the samples were deproteinised by ultrafiltration with centrifugal devices of 10 kD 
cut-off (Microsep Omega® 10 K, Pall Corporation, East Hills, NY, USA), for two 
hours, at 3000 x g at room temperature.
4.7 PRODUCTS
The Lactobacillus helveticus fermented milk product containing Ile-Pro-Pro and 
Val-Pro-Pro tripeptides (peptide milk) was produced by Valio Ltd, Helsinki, 
Finland, from heat-treated, low-lactose skimmed milk inoculated with single-
strain Lactobacillus helveticus (LBK 16 H strain) culture under aseptic conditions. 
The milk was fermented for 18–20 h in optimal growth conditions in order to 
reach a high proteolytic activity at +37ºC to a final pH of 4.0–4.2. In studies 
with fermented milk containing high concentrations (dose 50 mg/d) of Ile-Pro-Pro 
and Val-Pro-Pro, the Lactobacillus helveticus fermented milk was enriched with 
peptide concentrate. The Ile-Pro-Pro and Val-Pro-Pro (Bachem AG, Bubendorf, 
Switzerland) in drinking fluid were dissolved in tap water. In mineral water, the 
minerals calcium (calcium lactate gluconate), potassium (potassium citrate) and 
magnesium (magnesium chloride) were dissolved in boiled tap water. The daily 
doses of peptides and minerals are shown in Table 7. 
55
M A T E R I A L S  A N D  M E T H O D S
Ta
bl
e 7
. D
ai
ly 
do
se 
of
 p
ep
tid
es 
an
d 
m
in
er
al
s
Pe
pt
id
e 
m
ilk
Pe
pt
id
e 
w
at
er
 
Pe
pt
id
e 
an
d 
 
m
in
er
al
 w
at
er
M
in
er
al
 w
at
er
Ra
di
ol
ab
el
le
d 
IP
P
Ex
pe
ri
m
en
ta
l s
tu
di
es
, m
g/
kg
 o
f b
od
y 
w
ei
gh
t
St
ud
y 
I
IP
P 
2.
1 
an
d 
VP
P 
2.
1,
N
a 
38
, K
 3
84
, C
a 
25
6,
 M
g 
21
IP
P 
1.
4 
an
d 
 
VP
P 
1.
4
IP
P 
1.
6 
an
d 
VP
P 
1.
6,
 
N
a 
38
, K
 2
78
,  
Ca
 2
21
, M
g 
20
 
N
a 
36
, K
 2
63
,  
Ca
 2
09
, M
g 
19
St
ud
y 
II
7 
m
g/
kg
, r
ad
io
la
be
lle
d 
 
IP
P 
w
as
 2
.2
-2
.5
%
,  
th
e 
re
st
 u
nl
ab
el
le
d 
IP
P
Cl
in
ic
al
 s
tu
di
es
, d
ai
ly
 d
os
e 
m
g
St
ud
y 
III
IP
P 
2.
25
 a
nd
 V
PP
 3
, 
N
a 
48
, K
 4
65
, C
a 
30
0,
 M
g 
26
St
ud
y 
IV
IP
P 
22
.5
 a
nd
 V
PP
 3
0,
 
N
a 
12
3,
 K
 1
53
0,
 C
a 
69
0,
 M
g 
93
St
ud
y 
V
IP
P 
22
.5
 a
nd
 V
PP
 3
0,
 
N
a 
12
3,
 K
 1
53
0,
 C
a 
69
0,
 M
g 
93
St
ud
y 
VI
Pe
pt
id
e 
m
ilk
 1
: I
PP
 3
.4
 a
nd
 V
PP
 3
.7
,  
N
a 
69
, K
 4
80
, C
a 
31
0,
 M
g 
26
Pe
pt
id
e 
m
ilk
 2
: I
PP
 2
3.
2 
an
d 
VP
P 
26
.4
, 
N
a 
12
8,
 K
 1
00
0,
 C
a 
76
0,
 M
g 
72
IP
P 
  
= 
Ile
-P
ro
-P
ro
VP
P 
 
= 
Va
l-P
ro
-P
ro
56
M A T E R I A L S  A N D  M E T H O D S
4.8 STATISTICAL ANALYSIS
The results are expressed as means with standard deviations (SD) or with standard 
errors of the mean (SEM). The most important outcomes are reported with 95% 
confidence intervals (CI). The changes within treatment groups were analysed 
using the paired t-test. The differences in changes between treatment groups were 
compared using either a t-test for independent samples or analysis of covariance 
(ANCOVA) with covariates. In the case of longitudinal data, analysis of variance 
for repeated measurements was performed to compare the results of different 
treatment groups. SPSS (version 11.5; SPSS Inc, Chicago, IL, USA) and STATA 
(version 9.2; StataCorp, College Station TX, USA) were used for the statistical 
analyses.
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5.1 EFFECT OF PEPTIDE MILK ON  
BLOOD PRESSURE
Experimental studies (Study I and Jauhiainen et al.   
unpublished data)
Peptide milk tended to attenuate the development of hypertension in SHR and 
attenuated the development of hypertension in dTGR. At the end of the nine-
week treatment period (Study I), the systolic blood pressure in the peptide milk 
group was -16.9 mmHg (p=0.053) lower than in the control group. This finding 
was supported by unpublished data on dTGR, where the mean blood pressure 
value in the peptide milk group (n=10) was 173.5 mmHg during the three-week 
treatment period while that in the control group (n=15) was 192.2 mmHg, the 
difference between the groups being about -19.0 mmHg (p=0.023) (Jauhiainen et 
al. unpublished data). In SHR, a slight, non-significant, effect on blood pressure 
was also seen with pure tripeptides in water (-8.3 mmHg vs. water control, p=0.379) 
and with minerals (Ca, K, Mg) and tripeptides in water (-12.7 mmHg vs. water 
control, p=0.153). The beneficial effect on blood pressure with pure tripeptides was 
not seen in dTGR (Figure 8). 
5  R esults
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Figure 8. Treatment effects on systolic blood pressures in SHR (Study I) and in dTGR 
(Jauhiainen et al. unpublished data), mean ± SD.
Clinical trials (Study III, IV, VI) 
Baseline blood pressure values were measured using office blood pressure 
measurement (study iii, iv, vi). in the whole study group in study iii, the baseline 
values (mean ± sD) for systolic blood pressure were 151 ± 13 mmHg and those for 
diastolic blood pressure 96 ± 6 mmHg. in study iv, the systolic blood pressure 
values in repeated office blood pressure measurements were 149 ± 8 mmHg and 
diastolic blood pressure values 93 ± 6 mmHg. in study vi, the baseline systolic 
blood pressure values were 153 ± 14 mmHg and diastolic blood pressure values 95 
± 11 mmHg.
Systolic blood pressure tended to decrease more in the peptide milk group than 
in the placebo group. in study iii, the treatment effect was significant only in 
per protocol analysis [-6.7 mmHg (95% Ci -12.8 to -0.7), p=0.030], but not 
in intention-to-treat analysis. in study iv, the treatment effect was significant 
[-4.1 mmHg (95% Ci -6.6 to -1.8), p<0.001]. in study vi, a high dose of peptides 
lowered systolic blood pressure compared to the baseline level [-4.6 mmHg (95% 
Ci -8.4 to -0.8), p=0.018], but the treatment effect was not significant. 
Diastolic blood pressure tended to decrease in study iii, but the treatment effect 
was not significant even in the per protocol analysis [-3.6 mmHg (95% Ci -7.4 to 
0.1), p=0.059]. in study iv, diastolic blood pressure decreased more in the peptide 
milk group than in the placebo group and the treatment effect was significant 
[-1.8 mmHg (95% Ci -3.7 to 0.0), p=0.048]. in study vi, with a high dose of 
peptides, the diastolic blood pressure decreased compared to the baseline level 
[-3.7 mmHg (95% Ci -6.1 to -1.3), p=0.004], but the treatment effect was not 
significant (Figure 9). 
Study I
Unpublished 
data
Peptide milk
Peptide water
Minerals in water
Minerals + peptides in water
Peptide milk
Peptide water
Treatment effect (Treatment - water) 
on systolic blood pressure, mmHg 
-50 -40 -30 -20 -10 0 10 20 30 40 50
59
R E S U L T S
In Study VI, no significant changes in systolic or diastolic blood pressure were 
observed after the first 12-week intervention with low-dose peptide treatment.
In Study III, in the peptide milk group systolic and diastolic blood pressure 
fell by -17.7 ± 5.4 mmHg and -9.8 ± 5.6 mmHg, respectively, for subjects without 
medication (n=13) and by -16.1 ± 14.4 mmHg and -8.9 ± 8.4 mmHg for subjects 
with medication (n=9). In the placebo group systolic and diastolic blood pressure 
fell by -11.3 ± 14.0 mmHg and -4.3 ± 8.5 mmHg, respectively, for subjects without 
medication (n=10), and by -11.1 ± 18.4 mmHg and -8.8 ± 8.8 mmHg for subjects 
with medication (n=7). None of these results were significant. 
Figure 9. Treatment effects on systolic and diastolic blood pressures in Studies III, IV and 
VI, mean ± SD.
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5.2 EFFECT OF PEPTIDE MILK ON 
VASCULAR FUNCTION 
Experimental study (Study I) 
The most marked, maximal, cumulative relaxation response in vitro in the 
mesenteric artery and aorta in endothelium-dependent relaxation to acetylcholine 
was seen in the mineral + peptide group (p=0.023). No differences between the 
treatment groups were seen in the endothelium-independent relaxations to sodium 
nitroprusside.
Clinical studies (Study V, VI) 
Ambulatory arterial stiffness index (Study V)
During the 10-week intervention period, AASI improved significantly in the 
peptide milk group, but not in the placebo group (Table 8). The improvement 
in AASI was 12% in the peptide milk group and 5% in the placebo group as 
compared to baseline levels. There were no significant differences between the 
study groups in the AASI (p=0.40).
Table 8. Changes in AASI from baseline to the end of the 10-week treatment period. 
Baseline 
Mean (SD)
Change by week 10
Mean (95% CI)
p-value
Peptide milk, n=47 0.36 ± 0.15 -0.043 (-0.084 to -0.001) 0.043
Placebo, n=47 0.36 ± 0.17 -0.019 (-0.074 to 0.035) 0.47
Effect of peptide milk on arterial stiffness  
and endothelial function (Study VI)
AIx, as an indicator of improved vascular function, decreased significantly in the 
peptide milk group compared to the placebo group [peptide milk group -1.53% 
(95% CI -2.95 to -0.12), placebo group +1.20% (95% CI 0.09 to 2.32), p=0.013] 
(Figure 10). The improvement in arterial stiffness was more noticeable in males. 
After the 24-week treatment period, the AIx values were significantly lower in 
males in the peptide milk group compared with the placebo group [peptide milk 
group -2.30% (95% CI -4.31 to -0.28), placebo group +1.74% (95% CI 0.44 to 
3.04), p=0.004]. There was no difference in the change of AIx in females between 
the peptide milk group [-0.39%, (95% CI -2.34 to 1.56)] and the placebo group 
[+0.35%, (95% CI -1.77 to 2.48), p=0.90]. 
61
R E S U L T S
The Tr value did not differ between the groups. However, when comparing 
males, there was a difference between the groups [peptide group +1.7 ms (95% CI: 
-0.44 to 3.9), placebo group -2.1 ms (95% CI -4.1 to -0.1), p=0.022]. In women, 
the difference was not seen [peptide group -1.4 ms (95% CI -3.7 to 0.9), placebo 
group -1.6 ms (95% CI -5.2 to 1.9), p=0.58]. 
No differences between the groups were seen in the response to nitroglycerin-
induced endothelium-independent relaxation [peptide group +0.33% (95% CI: 
-1.31 to 1.98), placebo group +1.20% (95% CI -0.74 to -3.15), p=0.79]. The same 
applies to the response to salbutamol-induced endothelium-dependent relaxation 
[peptide group -0.64% (95% CI: -2.41 to 1.12), placebo group +0.82% (95% CI 
-1.12 to 2.75), p=0.61] after 24 weeks’ treatment. 
Figure 10. AIx values at the baseline before nitroglycerin and salbutamol administration 
and the change from baseline to 24 weeks (∆ AIx).  = peptide milk n=45,  = placebo 
n=44. 
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5.3 BLOOD PRESSURE  
LOWERING MECHANISMS
Experimental studies 
In Study I, the role of ACE inhibition as the mechanism by which Ile-Pro-Pro 
and Val-Pro-Pro lower blood pressure was investigated in SHR by measuring the 
plasma renin activity (PRA). The PRA of the peptide water group was lower than 
in the control group (p=0.042).  
In in vitro analysis, the contraction response to Ang I in the mesenteric artery 
rings tended to attenuate in SHR receiving the peptide milk (Study I) and in arterial 
rings from Sprague-Dawley rats preincubated with pure tripeptides (Jauhiainen et 
al. unpublished data).
Blood pressure lowering mechanisms were also studied using dTGR, which 
develop malignant hypertension due to increased Ang II formation (Jauhiainen et 
al. unpublished data). Peptide milk showed a clear attenuation in blood pressure 
values, but neither the peptide milk nor peptide water showed any signs of reduced 
Ang II production. There were no differences between the groups in Ang II-induced 
end-organ damage measured by renal morphology. The damage score was 3.3 ± 
0.2 in the dTGR control group (n=15), 3.0 ± 0.3 in the peptide milk group (n=10) 
and 2.8 ± 0.2 in the peptide water group (n=10) (p=0.53). 
Clinical studies 
In Study VI, the blood pressure lowering mechanism of peptide milk was evaluated 
by measuring arterial stiffness. In this study, pulse wave reflection induced by 
β2-adrenergic stimulation was not markedly improved [peptide milk group -0.64 
(95% CI: -2.41 to 1.12), placebo group 0.82 (95% CI: -1.12 to 2.75), p=0.61]. 
This suggests indirectly that improved endothelial NO release capacity is not the 
mechanism by which peptide milk mediates its favourable circulatory effects. 
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5.4 KINETICS OF  
ILE-PRO-PRO PEPTIDE
Radioactivity analyses 
In Study II, after a single intravenous administration of Ile-Pro-[14C]Pro, the mean 
blood concentration observed at 1 minute post-dose was 16.95 µg equiv/g. The 
highest blood concentration after a single oral administration of Ile-Pro-[14C]Pro 
was observed at two hours post-dose (6.79 µg equiv/g). The concentration of total 
radioactivity declined slowly after oral absorption and at 48 h was still 2.94 µg 
equiv/g. 
Excretion of radiolabelled Ile-Pro-Pro was measured from urine and faeces. 
A notable level of radioactivity was still present in the residual carcass and whole 
tissues collected at 48 h post-dose. Radioactivity was distributed in the body 
after oral administration of Ile-Pro-[14C]Pro. The highest concentrations of total 
radioactivity were observed in most tissues at 4 h post-dose, with considerable 
levels of radioactivity observed in the bone marrow, adrenals and aorta as well 
as in the liver, kidneys and spleen. Chromatographic and mass spectrometric 
analysis of plasma samples proved that Ile-Pro-[14C]Pro was present in each sample 
analysed because the component detected at ca. 12 minutes during size-exclusion 
chromatography experiments was shown by mass spectrometry analysis to be Ile-
Pro-Pro. 
Plasma protein-binding properties 
Ile-Pro-Pro at a concentration of 10 µM was incubated in 4% human serum 
albumin and human plasma for 30 minutes. After ultrafiltration, the concentrations 
of Ile-Pro-Pro found in the permeates were 100%. Pro-Pro concentrations in the 
permeates were 51% in human serum albumin and about 2% in human plasma 
after incubation and ultrafiltration. The in vitro tests thus showed that Pro-Pro 
attaches to plasma proteins (over 98%) whereas Ile-Pro-Pro is not bound. 
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Earlier experimental studies have shown that the bioactive peptides Ile-Pro-Pro 
and Val-Pro-Pro derived from milk casein have beneficial effects on blood pressure, 
while peptide milk has been shown to reduce blood pressure in clinical studies. 
However, the antihypertensive mechanisms, kinetics, long-term antihypertensive 
effects and the effects on vascular function in clinical use are not well known. This 
study investigated the blood pressure lowering effects and the effects on arterial 
stiffness of peptide milk in hypertensive subjects. The blood pressure lowering 
mechanisms of tripeptides Ile-Pro-Pro and Val-Pro-Pro and peptide milk, and the 
kinetics of Ile-Pro-Pro were investigated in these experimental studies. 
6.1 METHODOLOGICAL ASPECTS
Experimental studies 
Animal models
In the experimental studies, three different animal models were used to evaluate 
the blood pressure lowering mechanisms of Ile-Pro-Pro and Val-Pro-Pro and 
the kinetics of Ile-Pro-Pro. SHR is the most commonly used animal model for 
human essential hypertension. The animal model develops hypertension and its 
complications with increasing age. Even though this animal model is widely used, 
it has been criticised as not an appropriate model for human essential hypertension 
(for review, see Zicha and Kunes 1999). 
The other animal model used in the unpublished data, dTGR, is suitable for 
studying RAS-related mechanisms, the effects of ACE inhibitors, AT1 receptor 
6  Discussion
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blockers and Ang II-induced pathogenesis (Bohlender et al. 1997). This animal 
model develops severe hypertension and lethal cardiac and renal end-organ 
damage at 7 weeks of age (Luft et al. 1999). The effects of nutritional factors 
in this animal model have been evaluated in only a few studies. Magnesium 
supplementation and lipoic acid have been shown to have beneficial effects after 
three weeks’ treatment (Mervaala et al. 2003; Finckenberg et al. 2005). This model 
makes it possible to evaluate only rather short-term effects due to the malignancy 
of hypertension, whereas the treatment period in studies evaluating the effects of 
lifestyle modification on health should usually be relatively long. When the kinetics 
of a certain compound are investigated, the animal models used are usually healthy 
models. In the present study, Sprague-Dawley rats were used. 
Blood pressure measurement technique
Blood pressure was measured using the tail-cuff method. This method is relatively 
simple and suitable for a large number of animals as in the present study, and it has 
shown to have a good correlation with direct intra-arterial recordings. However, 
the tail-cuff method may overestimate blood pressure levels because of the stress 
caused by the environment. Furthermore, only systolic blood pressure values can 
be registered (Plehm et al. 2006). The overestimation of the blood pressure level 
can be minimised, if the same person measures the blood pressure during the 
whole study period and if the surroundings are quiet. These factors were taken into 
account in the present study. The rats were kept at +32°C for 15 minutes before the 
measurement to obtain reliable blood pressure values. However, this temperature 
also represents a stressful situation for rats and might raise their blood pressure 
(Kenney et al. 1995). For this reason, the duration of exposure to this temperature 
was kept exactly the same for each rat so this possible effect on blood pressure was 
the same in all the treatment groups.
Arterial responses
It has been shown in experimental and clinical trials that aging and hypertension 
interact and are associated with long-term changes in arterial structure and 
function. Injuries to relatively large arteries can cause the major complications of 
hypertension (for review, see Safar et al. 1998). It is therefore important to examine 
the effects of antihypertensive compounds on arterial function (Safar et al. 2001; 
Izzo and Mitchell 2007). In the present study, we used the mesenteric artery and 
aorta as models to evaluate the effects of blood pressure lowering interventions with 
Ile-Pro-Pro and Val-Pro-Pro and peptide milk on the functioning of these arteries. 
The mesenteric artery can be used as a model of a resistance artery and is suitable 
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for use in studies measuring precontractions and reproducible relaxation responses. 
The aorta, on the other hand, can be used as a model of a conduit artery. 
Clinical studies 
Study designs and products
All the clinical studies were carried out as randomised, double-blind, and placebo- 
controlled trials. The studies contained a run-in period before the intervention 
period. The intervention periods, 10 to 24 weeks, were considered long enough 
for a significant reduction in blood pressure levels, because in earlier studies with 
Ile-Pro-Pro and Val-Pro-Pro peptide milk, a reduction in blood pressure was seen 
after an eight-week treatment period (Hata et al. 1996; Seppo et al. 2002). No 
earlier clinical references to the effects of peptide milk containing Ile-Pro-Pro and 
Val-Pro-Pro on vascular function were available. 
The placebo product in all studies was similar in taste and appearance to 
the peptide milk. The placebo products were fermented milk drinks, just as the 
peptide milk. The subjects were well motivated and only about 3% withdrew 
from the studies after the run-in period. The subjects maintained normal diet and 
exercise habits throughout the study period, and the compliance for taking the 
study products daily was good in all studies. 
In all the studies, blood pressure was slowly reduced when the treatment 
(including that with placebo) was started. This is a common phenomenon in blood 
pressure trials, which is why the run-in period at the beginning of the study is 
important (Asmar et al. 2001). 
Blood pressure measurement techniques
Blood pressure was measured using three different techniques: office blood 
pressure measurement, home blood pressure registration and 24-hour ABPM. 
The office blood pressure measurement involves the biggest risk of variations and 
high blood pressure values, because even if all guidelines are followed, there is 
still variation. The prevalence of white coat hypertension in hypertension patients 
(office measurement) has been found to be approximately 20% (Pickering et al. 
1988; Verdecchia et al. 1995). For subjects with white coat hypertension, better 
blood pressure readings are obtained with home blood pressure measurement and 
24-hour ABPM. Home blood pressure measurements in hypertensive subjects 
have been reported to have high reproducibility and low placebo effect (Imai et 
al. 2001). The 24-hour ABPM is the gold standard and also covers the circadian 
rhythm (Giles 2006). 
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In the present study, a clear difference was shown between the office blood 
pressure measurement and the 24-hour ABPM. The average office baseline systolic 
blood pressure values were over 15 mmHg higher and diastolic blood pressure 
values were over 10 mmHg higher than the ambulatory values. The subjects in 
the office blood pressure measurement were mildly hypertensive (systolic blood 
pressure about 150 mmHg and diastolic 93 mmHg), but when blood pressure was 
measured with the ABPM, the blood pressure fell and the subjects were nearly 
normotensive (systolic blood pressure about 130 mmHg and diastolic 80 mmHg). 
This can be explained by the diurnal variation seen in ABPM, which includes, 
with healthy subjects, lower blood pressure values during the night (O'Brien et al. 
2003). 
Arterial responses
The effects of peptide milk on arterial stiffness were evaluated using a non-invasive 
PWA. In this analysis, the speed of the pulse going through arteries increases with 
increasing stiffness (Oliver and Webb 2003). When arterial stiffness is measured, 
the Clinical Applications of Arterial Stiffness advise that the subjects should not 
smoke or eat for at least three hours before the measurements and that they should 
have a 10-minute period of rest in a quiet room before the actual measurements 
(Van Bortel et al. 2002). These guidelines were taken strictly into account in the 
present study. 
When arterial stiffness is measured using PWA, different components of the 
waveform, such as the AIx, can be derived as markers of arterial stiffness, and 
the reproducibility of the markers is generally reported to be good (Wilkinson et 
al. 1998). The AIx was calculated as the difference between the first and second 
systolic peaks, expressed as a percentage of the central pulse pressure, and can be 
used as a measure of arterial stiffness. Increased aortic and carotid AIx have been 
shown to be an independent predictor of cardiovascular disease risk, mortality 
and morbidity (London et al. 2001; Kingwell et al. 2002; Nurnberger et al. 2002). 
Recent studies show that AIx in the radial artery, which was measured in the 
present study, is another independent risk marker for cardiovascular diseases and 
provides information equivalent to the carotid arterial AIx (Weber et al. 2004; 
Sugawara et al. 2007). 
The AASI is a novel index of vascular stiffness. AASI has been shown to 
correlate with aortic pulse wave velocity and with the central and peripheral systolic 
augmentation indexes (Li et al. 2006b). AASI has been shown to be an independent 
predictor of cardiovascular mortality and to be associated with organ damage in 
hypertensive patients (Leoncini et al. 2006; Li et al. 2006a). The measurement 
of AASI has also been criticised, and according to Westerhof et al. (2007), AASI 
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correlates with indicators of arterial stiffness but is not a measure of arterial stiffness 
(Westerhof et al. 2007). In the present study, the AASI values were within normal 
range according to the reported age-related AASI values, which are under 0.50 at 
20 years and under 0.70 at 80 years (Li et al. 2006b). 
6.2 EFFECTS OF PEPTIDE MILK  
ON BLOOD PRESSURE AND 
VASCULAR FUNCTION
BLOOD PRESSURE
Experimental studies  
Peptide milk attenuated the development of hypertension in dTGR and tended 
to attenuate it in SHR. A similar but less potent tendency was seen with pure 
tripeptides and tripeptides in combination with minerals (Ca, K, Mg) in SHR. The 
effects on blood pressure of peptide milk and the pure tripeptides Ile-Pro-Pro and 
Val-Pro-Pro have been shown in earlier experimental trials by our group with SHR 
(Sipola et al. 2001; Sipola et al. 2002a). The long-term effects and the differences 
between the peptide milk group and the control group were seen after five to eight 
weeks’ treatment (Nakamura et al. 1995b; Sipola et al. 2001; Sipola et al. 2002a): 
on the other hand, the effects of tripeptides have also been seen after a single oral 
administration (Nakamura et al. 1995b; Sipola et al. 2001; Sipola et al. 2002a). In 
the present study with SHR, the treatment period can therefore be considered long 
enough, even though significant differences could not be seen. In the study with 
dTGR, the treatment period was only three weeks because of the malignancy of 
hypertension and death of the animals, and therefore, the effects of peptide water 
on blood pressure may not have been seen during this treatment period.
The present study with SHR suggests that minerals may have an important 
role as blood pressure lowering components in peptide milk. The same tendency 
for attenuating the blood pressure values was seen with minerals as with pure 
tripeptides in water. In the study with SHR and dTGR, the peptide milk was the 
most effective. It tended to attenuate the development of hypertension in SHR and 
attenuated the development of blood pressure in dTGR. It is therefore suggested 
that peptide milk might also contain some other components that affect blood 
pressure. The effective components, such as minerals, might also be absorbed 
better from milk than from water (Kitts et al. 1992; Narva et al. 2004). The diet of 
the rats receiving peptide milk, mineral water or mineral+peptide water contained 
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about 0.6% more calcium and about 0.7% more potassium than the control diet 
because of the calcium and potassium contents of the drinking fluids. However, in 
earlier studies, the calcium supplementation showing attenuation in blood pressure 
values in SHR was 2 to 3% and that of potassium 3.5% (Pörsti 1992; Tolvanen 
et al. 1998). On the other hand, the blood pressure reductions observed in these 
studies were also more marked than in the present study. Therefore, the present 
study appears to indicate that, together with peptides, minerals might play an 
important role in the attenuation of hypertension. 
Clinical studies 
The peptide milk tended to lower blood pressure in all clinical studies. The blood 
pressure lowering effect was studied with two daily doses (about 5 mg and 50 
mg) of tripeptides. In earlier published clinical studies, the daily dose of different 
peptides or proteins has varied from 2.6 mg to 20000 mg (20g), but the blood 
pressure reduction did not seem to be related entirely to the peptide dose in these 
studies (Table 4). An interesting fact in these studies is that they report only 
positive results with milk peptides and proteins. This might be a bias in referring 
to this literature. However, because of these reported doses in the literature, it 
could be speculated that the peptide dose attains maximal efficacy with quite small 
doses and that higher doses do not give a better response, as is the case also with 
some other functional components such as plant stanols (Cater et al. 2005) and 
antihypertensive medication. 
In the present study, the blood pressure lowering effect was seen with 50 mg of 
tripeptides, and a tendency for lowering blood pressure was also seen when the dose 
was 5 mg. In Study VI, the effects of both doses were evaluated and the effect was 
only seen with the high peptide dose. One explanation for this could be the relatively 
high baseline blood pressure values, since the blood pressure values as inclusion 
criteria were measured using 24-hour ABPM. Therefore it could be that the small 
peptide dose in this trial was not effective enough to give results. On the other 
hand, in this trial blood pressure was measured during the intervention by office 
blood pressure measurement, which is the technique with the highest variation, i.e. 
small reductions in blood pressure values may not have been observed. 
At 10 to 24 weeks, the intervention periods in this study were relatively long 
compared with other studies with peptides. It is important to show that the blood 
pressure lowering effect is stable and lasts over a long period and that long-term use 
does not cause any adverse effects. Interestingly, it was shown in the present study 
that the blood pressure reduction response was more marked in women in Studies 
III and IV. Demographic characteristics cannot explain this difference. 
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The peptide milk contained more calcium, potassium and magnesium than 
the placebo products, and therefore some of the blood pressure lowering effect 
could be attributable to these minerals. However, minerals cannot fully explain the 
difference between the groups, because when comparing to the earlier studies, small 
reductions in blood pressure have been achieved with calcium supplementation of 
about 1200 mg/d, systolic blood pressure fell by about 2 mmHg and diastolic 
blood pressure by about 1 mmHg (van Mierlo et al. 2006) and with potassium 
supplementation of about 2900 mg/d systolic blood pressure fell by about 3 mmHg 
and diastolic blood pressure by about 2 mmHg (Whelton et al. 1997). In the present 
study, the subjects in the peptide milk group received 105–420 mg more calcium 
and 240–1080 mg more potassium than the placebo group. 
VASCULAR FUNCTION
Experimental studies 
In the experimental studies, an improvement in endothelium-dependent relaxation 
was seen with minerals+peptides in water. This is interesting because the peptide milk 
contained the same peptides and minerals. The intake of minerals was even slightly 
higher in the peptide milk group because of higher consumption. In addition, calcium 
absorption might be enhanced due to the caseinophosphopeptides in milk (Kitts et 
al. 1992; Narva et al. 2004). Minerals alone have been shown to have a positive 
effect on arterial responses. Calcium has been shown to enhance vasorelaxation 
in experimental trials (Mäkynen et al. 1995; Jolma et al. 2003; Kähönen et al. 
2003). In the present study, the extra calcium intake in the peptide milk group 
compared to the control group was, however, much smaller than the intake of 
calcium in earlier studies (Mäkynen et al. 1995; Jolma et al. 2003; Kähönen et al. 
2003). Potassium and magnesium also have beneficial effects on vascular function, 
and the positive effects of potassium might be mediated by increasing endothelial 
nitric oxide production (Mäkynen et al. 1995; Wu et al. 2006; Dorrance et al. 
2007). In the present study, the potassium intake was also only about one third of 
the intake in the earlier studies. However, even though the intakes of calcium and 
potassium were smaller in the present study than in the earlier studies, they could 
partly explain the positive effect. ACE inhibitors have also been shown to improve 
relaxation responses in rats, and the slight ACE inhibitory activity of Ile-Pro-Pro 
and Val-Pro-Pro might therefore partly explain this result (Mervaala et al. 1998b; 
Baluchnejadmojarad et al. 2004). 
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Clinical studies 
The clinical studies showed that peptide milk containing a high dose of tripeptides 
improves AIx and AASI in hypertensive subjects. This effect might be related to 
the improved sensitivity of vascular smooth muscle cells. In the present study, 
nitroglycerin administration was used to evaluate the endothelium-independent 
relaxation and salbutamol to evaluate the endothelium-dependent relaxation. 
Because no clear differences were seen between the groups after these measurements, 
the present study could not demonstrate that the clear vasodilation seen in the 
basal values with peptide milk is caused by the stimulation of endothelial NO 
release. However, because basal NO release by the endothelium is an important 
determinant of pulse wave reflection, it can be hypothesised that the peptide milk 
improves basal endothelial NO release or, on the other hand, PGI2 or EDHF 
formation, although the maximal capacity of the release of these compounds 
remained unaffected. The results in Tr in males also support beneficial effects of 
peptide milk. The Tr value was slightly increased in the peptide group, and because 
Tr is a risk factor for coronary heart disease (Hayashi et al. 2002; Weber et al. 
2004), this is an interesting finding. 
It is unlikely that the 24-week intervention period could cause any major 
changes in the elastic properties of the arterial wall. The mechanism is more likely 
to be a reduction in arterial tone. This could reduce arterial stiffness as a result of 
decreasing tension in vascular smooth muscle (Wilkinson et al. 2000).
The reduction in AIx was only seen in males in this study. However, the same 
active treatment also produced a more marked reduction in blood pressure in 
males. AIx increases with age and has been shown to be higher in women (Segers 
et al. 2007). The differences in age cannot explain this difference between the 
genders because the age was similar between the active and placebo groups and 
between genders. Female gender, on the other hand, could play some role in this 
difference. Central arterial elastic properties vary throughout the menstrual cycle 
in women (Hayashi et al. 2006), and the cycle was not taken into consideration in 
the present study. However, it cannot be concluded from these results that peptide 
milk is effective only in males, because the results on blood pressure in two other 
clinical studies (Studies III and IV) were the opposite. 
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6.3 BLOOD PRESSURE LOWERING 
MECHANISMS AND KINETICS OF 
ILE-PRO-PRO AND VAL-PRO-PRO
Blood pressure lowering mechanisms
A tendency for ACE inhibitory activity was seen in vitro but not in vivo. Therefore, 
the present study does not support the earlier findings on ACE inhibition by 
Ile-Pro-Pro and Val-Pro-Pro. This might be partly explained by the use of a very 
severely hypertensive animal model, dTGR, in the experimental studies. It has 
earlier been shown that these tripeptides decrease ACE activity in the aorta after a 
long-term intake and even after a single oral administration (Nakamura et al. 1995b; 
Nakamura et al. 1996). It has also been shown in SHR that these tripeptides in 
fermented milk increase plasma renin activity, which is a marker of ACE inhibition 
(Sipola et al. 2002a). In the present study, no differences were seen in PRA values 
between the groups and PRA value was even lower in the peptide water group than 
in the control group. It is possible that the blood pressure lowering mechanism 
behind Ile-Pro-Pro and Val-Pro-Pro could be explained by an inhibition of other 
enzymes involving the renin-angiotensin-bradykinin system. Like ACE, cathepsin 
G, CAGE and chymase produce Ang II from Ang I (Kramkowski et al. 2006) 
(Figure 2). Chymase is located intracellularly, mainly in the mast cells, and has also 
been demonstrated in endothelial and vascular smooth muscle cells (Urata et al. 
1993; Tom et al. 2003). Inhibition of chymase cannot explain the attenuation of 
the development of hypertension in rats, because Ang II production is dependent 
on ACE in rats (Kirimura et al. 2005; Miyazaki et al. 2006). However, because the 
relative peptide doses in humans are much smaller than in rats, and the results were 
still significant, chymase could play a role in the blood pressure lowering effect in 
humans. The minor ACE inhibition, on the other hand, could be enough to show 
effects in SHR but not in dTGR. Proline and valine have been shown to inhibit 
arginase in vitro (Dabir et al. 2006). According to this data, Ile-Pro-Pro and Val-
Pro-Pro might theoretically act as arginase inhibitors and inhibit the production of 
ornithine in order to get more L-arginine for the NO production. It can therefore 
be hypothesised that some other enzymes besides ACE in the RAS or some other 
systems might also play a role in the beneficial cardiovascular effects of Ile-Pro-Pro 
and Val-Pro-Pro. 
Kinetics
Considering that the tripeptides Ile-Pro-Pro and Val-Pro-Pro are able to lower blood 
pressure, it can be assumed that they must be absorbed intact from the intestine 
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or metabolised into the active components and then reach the target organ. It 
has been demonstrated that Ile-Pro-Pro and Val-Pro-Pro are absorbed from the 
gastrointestinal tract, but the evidence for this has been limited, and no data have 
been presented concerning the tissue distribution, excretion and time-dependent 
kinetics of these tripeptides. Masuda et al. (1996) detected the tripeptides Ile-Pro-
Pro and Val-Pro-Pro in the aorta after oral administration to the rats (Masuda et 
al. 1996). The average dose of tripeptides in that study was approximately 0.36 mg/
kg, whereas in the present study the dose of Ile-Pro-Pro was much higher, 7 mg/
kg, based on the earlier studies (Sipola et al. 2001; Sipola et al. 2002a). Masuda 
et al. (1996) identified the absorbed tripeptides in two collected peptide fractions 
from the chromatographic separation of the extract of the aorta by amino acid 
composition, and determined that the amino acid composition could correspond 
with Ile-Pro-Pro and Val-Pro-Pro. Satake et al. (2002) have reported Val-Pro-Pro 
being transported via the Caco- 2 cell monolayer by paracellular diffusion in vitro, 
although high amounts of tripeptides are also degraded into amino acids (Satake 
et al. 2002). In a very recent study, the absorption of Ile-Pro-Pro was evaluated by 
measuring the plasma concentration of the peptide before and after intake. The 
plasma concentration increased after the intake of Ile-Pro-Pro, and it was therefore 
thought that Ile-Pro-Pro was absorbed through the intestine and reached the 
circulation undegraded (Foltz et al. 2007). In the present study in rats, the maximal 
concentration of radiolabelled Ile-Pro-Pro in blood after oral administration was 
about one-third of that seen after intravenous administration. Oral absorption 
reached the maximal level after one to six hours. 
The present study showed that, in rats, lle-Pro-Pro is absorbed intact from 
the gastrointestinal tract after a single oral dose. Radiolabelled Ile-Pro-Pro was 
detected from several tissues and its excretion was slow; even after 48 hours, the 
radiolabelled peptide had not been completely excreted. The protein-binding 
properties were also evaluated, and it was shown that Ile-Pro-Pro did not bind to 
albumin or to other plasma proteins, whereas the dipeptide Pro-Pro was almost 
entirely bound to plasma proteins. These two peptides are similar in acid nature 
and therefore acid nature is not proposed to explain this protein binding difference. 
Concerning medicines, only the unbound part is pharmacologically active because 
the protein-bound part cannot cross biological membranes and is therefore unable 
to reach the target organ (Limberis et al. 2007). This supports the hypothesis that 
the blood pressure lowering effect is mediated via free Ile-Pro-Pro.
The kinetic study gave evidence that Ile-Pro-Pro might accumulate in 
tissues related to blood pressure regulation. Tissue-located RAS is present in the 
brain, kidneys, adrenal cortex, heart and blood vessels, and in the present study 
considerable radioactivity levels were found in the adrenals, aorta and kidneys. 
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6.4 CLINICAL RELEVANCE
Blood pressure
In the present study, the reductions in blood pressure values in the peptide 
group compared to the placebo group in the three clinical studies were 2.0 to 
6.7 mmHg in systolic blood pressure and 1.8 to 3.6 mmHg in diastolic blood 
pressure. Meta-analysis of 17 randomised trials of antihypertensive treatment in 
the literature shows that reductions of 10–12 mmHg in systolic blood pressure and 
5–6 mmHg in diastolic blood pressure reduce the incidence of stroke by about 
38% (MacMahon and Rodgers 1996). A reduction of 2 mmHg in systolic blood 
pressure reduces the overall expected risk of stroke by about 4%, as it does the risk 
for myocardial infarction. With this blood pressure reduction, the cost savings in 
terms of treatment of stroke and myocardial infarction were also marked (Selmer 
et al. 2000). Furthermore, a reduction in systolic blood pressure of about 8 mmHg 
and in diastolic blood pressure of about 4 mmHg have been shown to reduce the 
incidence of dementia by 50% from about 8 to 4 cases per 1000 patient-years 
(Staessen et al. 2007). 
Arterial stiffness
Arterial stiffness parameters such as AIx and Tr have been shown to be risk factors 
for cardiovascular events (Nurnberger et al. 2002; Weber et al. 2004). Patients 
with normal angiograms have significantly less arterial stiffness than subjects with 
evidence of obstructive coronary disease at angiography. Pulse wave velocity (Tr 
can be used as a substitute) was about 0.8 ms (9%) higher and AIx about 5.5% 
(23.5%) higher (Covic et al. 2005). Every 10% increase in AIx augments the risk of 
major adverse cardiovascular events (such as cardiovascular death, heart attack or 
stroke) by 28% in patients with coronary artery disease (Chirinos et al. 2005). In 
the present study, the change in AIx value was about -12% in the peptide group vs. 
the placebo group. This result can be considered clinically significant.  
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Safety
Peptide milk is a milk product fermented by the Lactobacillus helveticus bacteria, 
which have been generally used in cheese-making. In the present study, the 
tolerability of the peptide milk was evaluated in long-term use (21 weeks) and 
with high doses of tripeptides (10 and 24 weeks). This was done by asking the 
subjects whether or not they had noticed any adverse effects during the intervention 
period. A few adverse events were reported and they were similar in both groups. 
No changes in the safety markers (blood cell count, serum creatinine, urate and 
gamma glutamyl transferase) were observed. Similarly, adverse effects were not 
reported in earlier randomised controlled trials with milk products containing 
the tripeptides Ile-Pro-Pro and Val-Pro-Pro (Hata et al. 1996; Seppo et al. 2002; 
Mizushima et al. 2004; Tuomilehto et al. 2004), and in the current literature, no 
references concerning about the allergenicity of these tripeptides have been found. 
Peptide milk can therefore be considered a safe alternative for the dietary treatment 
of hypertension and vascular function. 
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The present study investigated the effects of the peptide milk containing the 
tripeptides Ile-Pro-Pro and Val-Pro-Pro on blood pressure and arterial stiffness in 
hypertensive subjects and the blood pressure lowering mechanisms behind these 
tripeptides and kinetics by using different experimental models. The main findings 
in the present study are as follows:
1. Experimental
The ACE inhibitory activity of Ile-Pro-Pro and Val-Pro-Pro does not explain  `
their blood pressure lowering effect, and it can be hypothesised that some 
other enzymes in the RAS might also play a role in this effect. 
Using radiolabelled Ile-Pro-Pro, the tripeptide was shown to be absorbed  `
partly intact from the gastrointestinal tract, and considerable radioactivity 
levels were distributed in tissues related to the RAS.
2. Clinical
The peptide milk containing the tripeptides Ile-Pro-Pro and Val-Pro-Pro  `
reduced blood pressure in long-term use in hypertensive subjects when 
blood pressure was measured by using 24-hour ABPM. 
The peptide milk reduced arterial stiffness. It can be suggested that this  `
effect of peptide milk is mediated via improved basal endothelial NO 
release, reduced blood pressure or arterial tone, although the maximal 
capacity of NO release remained unaffected.
7  Summary and 
Conclusions
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In conclusion, the peptide milk lowered blood pressure and arterial stiffness in 
hypertensive subjects. The tripeptide Ile-Pro-Pro is absorbed from the intestine and 
might accumulate in tissues, including those related to the RAS. The precise blood 
pressure lowering mechanism of the peptide milk remains to be studied.
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